Effect of porcine reproductive and respiratory syndrome (PRRS) modified-live virus (MLV) interventions on growth performance of infected growing pigs under field conditions by Amorim Moura, Cesar Augusto
Graduate Theses and Dissertations Iowa State University Capstones, Theses and Dissertations 
2020 
Effect of porcine reproductive and respiratory syndrome (PRRS) 
modified-live virus (MLV) interventions on growth performance of 
infected growing pigs under field conditions 
Cesar Augusto Amorim Moura 
Iowa State University 
Follow this and additional works at: https://lib.dr.iastate.edu/etd 
Recommended Citation 
Amorim Moura, Cesar Augusto, "Effect of porcine reproductive and respiratory syndrome (PRRS) 
modified-live virus (MLV) interventions on growth performance of infected growing pigs under field 
conditions" (2020). Graduate Theses and Dissertations. 18271. 
https://lib.dr.iastate.edu/etd/18271 
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and 
Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and 
Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, 
please contact digirep@iastate.edu. 
Effect of porcine reproductive and respiratory syndrome (PRRS) modified-live virus 





Cesar Augusto Amorim Moura 
 
 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
Major: Population Sciences in Animal Health 
 
Program of Study Committee: 
Daniel C. L. Linhares, Major Professor 







The student author, whose presentation of the scholarship herein was approved by the program 
of study committee, is solely responsible for the content of this dissertation. The Graduate 
College will ensure this dissertation is globally accessible and will not permit alterations after a 








Copyright © Cesar Augusto Amorim Moura, 2020. All rights reserved. 
ii 
DEDICATION 
This dissertation is dedicated to all my family and friends. In special to my mother 
Marcia Aparecida Amorim Moura and to my sister Isabela Amorim Moura, for all the love, 
support, and kindness that inspired me to be a better person and motivated me to keep following 
all my objectives in life.  
iii 
TABLE OF CONTENTS 
Page 
LIST OF FIGURES .........................................................................................................................v 
LIST OF TABLES ........................................................................................................................ vii 
ACKNOWLEDGMENTS ........................................................................................................... viii 
ABSTRACT ................................................................................................................................... ix 
CHAPTER 1. GENERAL INTRODUCTION ................................................................................1 
About This Dissertation ............................................................................................................. 1 
Background ................................................................................................................................ 1 
References.................................................................................................................................. 6 
CHAPTER 2. ASSESSMENT OF THE IMPACT OF VACCINATING PRRSV POSITIVE-
STABLE BREEDING HERDS WITH ATTENUATED PRRSV ON THE SUBSEQUENT 
NURSERY PIG PERFORMANCE ...............................................................................................10 
Abstract .................................................................................................................................... 10 
Background .............................................................................................................................. 12 
Materials and Methods ............................................................................................................ 13 
Study design ....................................................................................................................... 13 
Settings ............................................................................................................................... 14 
Eligibility and exclusion criteria ........................................................................................ 15 
Study groups and outcomes ................................................................................................ 15 
Statistical methods .............................................................................................................. 16 
Results...................................................................................................................................... 17 




CHAPTER 3. ASSOCIATION OF WILD-TYPE PRRSV DETECTION PATTERNS WITH 
MORTALITY OF MLV-VACCINATED GROWING PIG POPULATIONS.............................27 
Abstract .................................................................................................................................... 27 
Introduction.............................................................................................................................. 29 
Materials and Methods ............................................................................................................ 31 
Study design ....................................................................................................................... 31 
Eligibility criteria of the study population ......................................................................... 32 
Sampling and Diagnostics .................................................................................................. 33 
Statistical analyses .............................................................................................................. 34 
Results...................................................................................................................................... 35 
PRRSV-1 detection ............................................................................................................ 35 
iv 
PRRSV-2 patterns .............................................................................................................. 38 




CHAPTER 4. COMPARISON OF PRODUCTION AND ECONOMIC PERFORMANCE 
BETWEEN BATCHES OF NURSERY PIGS VACCINATED WITH FULL OR HALF DOSE 
OF ATTENUATED PRRSV VACCINE, UNDER FIELD CONDITIONS .................................48 
Summary .................................................................................................................................. 48 
Introduction.............................................................................................................................. 49 
Materials and Methods ............................................................................................................ 50 
Study design ....................................................................................................................... 50 
Study population................................................................................................................. 52 
Variables ............................................................................................................................. 52 
Statistical Analyses............................................................................................................. 53 
Results...................................................................................................................................... 56 
Productivity performance comparison ............................................................................... 58 
Economic performance comparison ................................................................................... 60 
Discussion ................................................................................................................................ 61 
Implications ............................................................................................................................. 64 
Conflicts of interest.................................................................................................................. 64 
References................................................................................................................................ 64 
CHAPTER 5. COMPARISON OF VIRUS DETECTION, PRODUCTIVITY, AND 
ECONOMIC PERFORMANCE BETWEEN BATCHES OF GROWING PIGS VACCINATED 
WITH TWO DOSES OR ONE DOSE OF PRRS MLV VACCINE, UNDER FIELD 
CONDITIONS ...............................................................................................................................66 
Abstract .................................................................................................................................... 66 
Introduction.............................................................................................................................. 68 
Materials and Methods ............................................................................................................ 69 
Study design ....................................................................................................................... 69 
Eligibility and exclusion criteria of the study population .................................................. 71 
Vaccination program .......................................................................................................... 71 
Diagnostic monitoring ........................................................................................................ 72 
Statistical analyses .............................................................................................................. 73 
Results...................................................................................................................................... 76 
Virus detection comparison ................................................................................................ 77 
Productivity performance comparison ............................................................................... 79 
Economic performance comparison ................................................................................... 82 
Discussion ................................................................................................................................ 84 
Conclusions.............................................................................................................................. 87 
Funding .................................................................................................................................... 88 
Conflict of Interest ................................................................................................................... 88 
References................................................................................................................................ 88 
CHAPTER 6. GENERAL CONCLUSIONS .................................................................................93 
v 
LIST OF FIGURES 
Page 
Figure 2-1. Study design. .............................................................................................................. 14 
Figure 3-1. Study design. .............................................................................................................. 32 
Figure 3-2. Patterns of wild-type PRRSV-1 detection over time, based on clustering 
analysis. .................................................................................................................... 36 
Figure 3-3. Wean-to-finish mortality by patterns of PRRSV-1 detection (means with 
standard errors). ........................................................................................................ 37 
Figure 3-4. Patterns of wild type PRRSV-2 detection over time, based on clustering 
analysis, of batches that originated from PRRSV stable (Holtkamp et al., 2011) 
sow farms and with at least one wt-PRRSV-2 detection during the growing 
phase. ........................................................................................................................ 39 
Figure 3-5. Wean-to-finish mortality by patterns of PRRSV-2 detection over time (means 
with standard errors). ................................................................................................ 40 
Figure 3-6. Wean-to-finish mortality by patterns of PRRSV-2 detection over time and by 
PRRS MLV vaccination dose (means with standard errors). ................................... 42 
Figure 4-1. Study design. .............................................................................................................. 51 
Figure 4-2. Overview of sample size for all blocks at each sow farm. ......................................... 57 
Figure 4-3. Comparison of nursery mortality rate between batches of pigs vaccinated with a 
full PRRS MLV vaccine dose and batches vaccinated with a half dose of the 
same vaccine (means with standard errors). ............................................................. 58 
Figure 4-4. Comparison of nursery average daily gain between batches of pigs vaccinated 
with a full PRRS MLV vaccine dose and batches vaccinated with a half dose 
of the same vaccine (means with standard errors). ................................................... 59 
Figure 4-5. Comparison of nursery feed conversion between batches of pigs vaccinated 
with a full PRRS MLV vaccine dose and batches vaccinated with a half dose 
of the same vaccine (means with standard errors). ................................................... 59 
Figure 4-6. Sensitivity analysis of the benefit-cost ratio of the full MLV vaccination, with 
varying feeder pig prices and varying vaccination costs. ......................................... 61 
vi 
Figure 5-1. Study design. .............................................................................................................. 70 
Figure 5-2. Proportion of wild-type PRRSV detection in oral fluids samples over time for 
one dose and two doses groups. ............................................................................... 78 
Figure 5-3. Log counts of wild-type PRRSV RNA per ml of oral fluids over time for one 
dose and two doses groups. ...................................................................................... 79 
Figure 5-4. Comparison of wean-to-finish mortality rate between one dose and two doses 
groups, by source sow farm PRRSV status (means and standard errors). ............... 80 
Figure 5-5. Comparison of wean-to-finish mortality rate between one dose and two doses 
groups, by the frequency and the diversity of wild-type PRRSV detection. ............ 81 
Figure 5-6. Sensitivity analysis of the benefit-cost ratio varying vaccination costs and 
market pig prices. ..................................................................................................... 84 
vii 
LIST OF TABLES 
Page 
Table 2-1. Baseline demographic data of study groups. ............................................................... 17 
Table 2-2. Nursery mortality rate of the post-mass sow vaccination groups, compared to the 
baseline group. .......................................................................................................... 18 
Table 2-3. Average daily gain of the post-mass sow vaccination groups, compared to the 
baseline. .................................................................................................................... 19 
Table 2-4. Feed conversion of the post-mass sow vaccination groups, compared to the 
baseline group. .......................................................................................................... 20 
Table 2-5. Description of overall nursey productivity of each post-mass sow vaccination 
group and the baseline group. ................................................................................... 21 
Table 2-6. Description of overall nursey productivity of all four post-mass sow vaccination 
groups and four baseline groups. .............................................................................. 22 
Table 3-1. Wean-to-finish mortality results of PRRSV-2 detection patterns, reported by the 
two different geographical regions of the study. ...................................................... 41 
Table 4-1. Production and economic parameters of half MLV dose group and full MLV 
dose group. ............................................................................................................... 55 
Table 4-2. Baseline demographic characteristics of half MLV dose group and full MLV 
dose group. ............................................................................................................... 57 
Table 4-3. Economic performance comparison between half MLV dose group and full 
MLV dose group....................................................................................................... 60 
Table 5-1. Productivity and economic parameters of one dose and two doses groups. ............... 75 
Table 5-2. Baseline demographic characteristics of one dose and two doses groups................... 77 
Table 5-3. Wean-to-finish average daily gain (ADG) comparison between one dose and two 
doses gro ................................................................................................................... 81 
Table 5-4. Wean-to-finish feed conversion (FC) comparison between one dose and two 
doses groups. ............................................................................................................ 82 
Table 5-5. Economic performance comparison between one dose and two doses groups. .......... 83 
viii 
ACKNOWLEDGMENTS 
I would like to thank my committee chair, Dr. Daniel Linhares, and my committee 
members, Dr. Holtkamp, Dr. Ramirez, Dr. O’Connor, and Dr. Wang, for their guidance and 
support throughout the course of this research. 
Also, I would like to thank the FieldEpi team: Gustavo, Marcelo, Will, Gaurav, Giovani, 
Edison and Henry for all the support and friendship throughout these four years.  
Special thanks to Dr. Reid Philips, for the support on my work since the beginning, 
always providing good advices and sharing some of his lifetime experience. 
In addition, I would also like to thank my friends, colleagues, the department faculty and 
staff for making my time at Iowa State University a wonderful experience. I want to also offer 
my appreciation to those who were willing to participate in my studies and observations, without 
whom, this dissertation would not have been possible. 
ix 
ABSTRACT 
Porcine reproductive and respiratory syndrome (PRRS) virus is a swine-specific pathogen 
that causes ongoing significant impact to the pig production. PRRS modified-live virus (MLV) 
vaccines are widely used to expose swine populations and mitigate the consequences of wild-
type PRRS virus (PRRSV) infections. There are several factors affecting vaccine efficacy under 
field conditions, including timing of exposure, genetic diversity of wild-type PRRSV, and 
immune status of growing pigs at the time of infection. Thus, there is the need to further 
understand the dynamics of viral infections in growing pigs, as well as the effect of different 
immunization strategies upon specific scenarios encountered in field conditions. This dissertation 
was conducted with the general objective to evaluate the performance of growing pig 
populations vaccinated with different protocols of PRRS MLV vaccine and naturally challenged 
with wild-type PRRSV, in field conditions.  
The first Chapter of this dissertation presents background information on PRRSV impact 
on growing pigs, and presents important unmet needs regarding use of immunization strategies to 
mitigate the consequences of infection of growing pigs under field conditions. 
Chapter two introduces the impact of mass vaccinating sows from PRRSV positive-stable 
farms, using PRRS MLV vaccine, on the subsequent nursery pig production performance. 
Nursery pig batches that were started up to twelve weeks after the PRRS MLV mass sow 
vaccination events were classified into four post-mass sow vaccination groups, while batches 
started up to six weeks before the mass interventions were classified into the baseline production 
group. The post-mass sow vaccination groups had significantly higher mortality rate than the 
baseline group. The post-mass sow vaccination groups had lower number of pigs produced, but 
with a higher weight gain per pig, compared to the baseline group. Overall, the ratio of the total 
x 
weight produced by the four post-mass sow vaccination groups over the weight produced by four 
baseline production groups of the same size was 1.02. According to the results of this study, 
mass vaccination of sows with PRRS MLV vaccine with the intent to immunize swine breeding 
herds to PRRSV was not associated with a negative impact on the productivity of the batches of 
nursery pigs flowing downstream. 
Chapter three identifies common patterns of wild-type PRRSV RNA detection on oral 
fluids samples collect from MLV-vaccinated growing pig populations, and assesses how the 
different wild-type PRRSV detection patterns in the field associates with the mortality rate of 
growing pigs. It was demonstrated that more than 90% of the batches of growing pigs were 
detected with wild-type PRRSV-2 (aka North-American), while 38% of the batches were 
detected with wild-type PRRSV-1 (aka European PRRSV). Growing pig mortality was higher in 
batches with wild-type PRRSV-2 detection in earlier stages of life. However, detection of wild-
type PRRSV-1 was not associated with significant increase of growing pig mortality. Mortality 
rate of batches with wild-type PRRSV-2 detection in earlier stages of life was lower when pigs 
were vaccinated with two doses of PRRS MLV vaccine, compared to batches that received only 
one dose. Results presented in this study suggested that early wild-type PRRSV-2 exposure on 
pig populations was associated with higher wean-to-finish mortality. Additionally, results 
suggested that vaccination with two PRRS MLV doses was associated with lower mortality rate, 
when growing pig populations had early wt-PRRSV-2 exposure. 
Chapter four describes a retrospective cohort study comparing productivity and economic 
performance between batches of nursery pigs vaccinated with a full dose of PRRS MLV vaccine 
and batches vaccinated with a half dose of the same vaccine, following natural exposure to wild-
type PRRSV. The full MLV dose group had significantly higher average daily gain than the half 
xi 
MLV dose group. However, no significant differences were detected on the mortality rate and on 
the feed conversion between study groups. Results suggested that the vaccination of pigs with 
one full dose of PRRS MLV vaccine was associated with improved nursery pig productivity and 
nursery pig profitability, compared to the vaccination with only half dose of the same vaccine. 
Chapter five consists of a randomized field trial to compare virus detection, productivity 
and economic performance between growing pig batches vaccinated with two doses or one dose 
of Ingelvac PRRS® MLV vaccine, in commercial swine operations. Under the conditions of this 
study, the proportion of wild-type PRRSV detection on oral fluids samples and the log counts of 
viral RNA per ml of oral fluids from the two doses group was lower than the one dose group, 
when batches originated from PRRSV positive-stable farms. The mortality rate of the two doses 
group was significantly lower than that of the one dose group, with a higher effect size on 
batches originated from PRRSV positive-unstable sow farms and on batches with higher 
frequency and with higher diversity of wild-type PRRSV detection. Overall, it was economically 
beneficial to use the second dose of MLV vaccination to immunize growing pigs compared to 
using only one MLV vaccination dose, especially when pig batches were originated from 
PRRSV positive-unstable sow farms. Under the study conditions, vaccinating growing pig 
batches with two doses of PRRS MLV vaccine was a useful strategy to immunize growing pigs 
against PRRSV, lowering the wild-type PRRSV detection, lowering mortality rate, and 
increasing profitability, compared to batches of growing pigs that received a single dose of the 
same vaccine. 
Results presented in this dissertation provide field-relevant information to guide 
veterinarians and producers to make evidence-based decisions to proactively influence herd 
immunity of growing pig populations at risk of wild-type PRRSV infection, and consequently 
xii 
maximize pig performance and increase the success of projects to control and eliminate PRRSV 




CHAPTER 1.    GENERAL INTRODUCTION 
About This Dissertation 
This dissertation is structured in six chapters. Chapter one presents a general introduction 
by providing background, stating the problem, identifying the gap of knowledge, and explaining 
the context of each research chapter (Chapters two to five). Chapter six briefly restates the 
problem, provides a general discussion about findings in this dissertation, and highlights how the 
work presented can be helpful to fill the gap of knowledge described in Chapter one. 
 
Background 
Porcine reproductive and respiratory syndrome (PRRS) is a swine-specific disease caused 
by PRRS virus (PRRSV). Two PRRSV species are described within the Arteriviridae family 
sharing worldwide distribution, with PRRSV-1 predominant in Europe and PRRSV-2 
predominant in the Americas and Asia. Both PRRSV species are detected in the US and most 
swine-producing countries with a few exceptions. The clinical disease in swine populations is 
characterized by severe reproductive losses in sow farms and respiratory syndrome in growing 
pigs, leading to a reduction in growth performance and increasing pig mortality [1]. 
In 2005, the total cost of productivity losses due to PRRSV in the US was estimated to be 
$560 million annually [2]. A study from 2013 updated the annual costs due to the virus to $664 
million per year, with the majority (55%) of the economic impact on the growth production 
phase ($ 362 million/year) [3]. This significant impact of PRRSV in productivity has motivated 
the development of PRRSV control and elimination programs [4, 5], population-based methods 




Vaccination against PRRSV with attenuated viruses as well as inoculation with live field 
(aka wild-type) virus provides late but effective protection against subsequent challenge with the 
same or closely related viruses [11, 12]. However, only partial protection is expected when 
animals are subsequently challenged with heterologous strains [10, 13, 14]. PRRS modified live 
virus (MLV) vaccines are widely used around the world to expose swine populations to PRRSV 
and mitigate the consequences of wild-type virus infections [13, 15].  
A study published in 2014 reported that breeding herds with a recent history of PRRSV 
exposure recovered the baseline productivity and started producing piglets consistently PRRSV-
negative significantly sooner after a PRRSV outbreak than herds with no prior immunity [16]. 
The same study also showed that farms using PRRS MLV vaccine to expose the sows right after 
the PRRSV outbreak recovered the baseline productivity significantly sooner than farms using 
wild-type virus inoculation to expose the sows [16]. In response, there is an increasing number of 
breeding herds regularly immunizing their sows with PRRS MLV products in recent years [17].  
PRRS MLV vaccination has also been an effective tool to immunize growing pigs and 
reduce losses attributed to PRRSV in the post-weaning phase. It has been demonstrated that 
PRRS MLV vaccination of pigs, with one full dose, significantly reduced clinical consequences 
of subsequent heterologous challenge on growing pigs, compared to pigs that were left 
unvaccinated [18-24]. Due to the high genetic diversity of circulating virus in the field, there is 
the need to further improve the efficacy of PRRS MLV vaccines against field heterologous 
viruses. In order to improve the immunogenicity of MLV vaccines, researchers worldwide have 
been improving vaccine and vaccination technologies. 
Studies have demonstrated that although recombinant MLV vaccines which induce the 




heterologous virus, clinical protection was not improved compared to the traditional MLV 
vaccine [25, 26]. The strategy of injecting pigs with a DNA vaccine and applying a PRRS MLV 
vaccine after a few weeks also improved the immune response against heterologous PRRSV 
infection. However, further improvements are still needed to confer greater heterologous clinical 
protection on pigs, compared to the MLV vaccination alone [27, 28].  
Different protocols of PRRS MLV vaccination on pigs have been proposed. The 
application of two PRRS MLV vaccine doses, thirty days apart, has been described as an attempt 
to control and eliminate PRRSV from finishing populations [29, 30]. The hypotheses for 
applying multiple doses of vaccine were that it would reduce the spread of wild-type virus and 
reduce the risk of improper or missed vaccinations of pigs within the population. However, there 
is limited information about the effect of different PRRS MLV vaccination doses on health and 
growth performance of growing pigs subsequently challenged in the field with heterologous 
viruses. A study presented in the International Pig Veterinary Society Congress in 2016 used 
statistical process control analysis to conclude that groups of growing pigs immunized with a full 
dose of PRRS MLV vaccine had lower wean-to-finish mortality rate than prior groups that were 
vaccinated with only half of the dose of the same vaccine [31]. 
Many PRRS MLV vaccine efficacy studies reported in the literature were conducted 
using challenge models under experimental conditions [13]. However, results from these 
experiments need to be interpret with caution in order to understand how natural virus infections 
can impact the performance of growing pig populations in the field. Field studies have shown 
that the wild-type virus exposure on growing pig populations is not homogeneous [32, 33]. There 
was important variation in the frequency and in the timing of PRRSV detection in growing pigs 




samples collected over time from growing pigs on different pens of a single barn was also 
different [33]. Therefore, in order to guide producers and veterinarians with evidence-based 
information on how different strategies of PRRSV MLV vaccination can help to reduce PRRSV-
associated losses on growing pig populations naturally challenged in the field, more studies 
conducted under field conditions are needed.  
This dissertation was conducted with the general objective to evaluate the productivity 
performance of growing pig populations vaccinated with different protocols of PRRS MLV 
vaccine and subsequently challenged naturally with wild-type PRRSV, under field conditions. 
Chapter Two is entitled “Assessment of the impact of vaccinating PRRSV positive-stable 
breeding herds with attenuated PRRSV on the subsequent nursery pig performance.” This 
chapter describes the association of the practice of mass vaccinating sows from PRRSV positive-
stable farms, using PRRS MLV vaccine, with the subsequent nursery pig productivity. Nursery 
pig batches that were started up to twelve weeks after the PRRS MLV mass sow vaccination 
events were classified into four post-mass vaccination groups, while batches started up to six 
weeks before the mass interventions were used to establish the baseline production group. 
Nursery pig productivity described by all post-mass vaccination groups were assessed and 
compared to the productivity of the baseline production group. 
Chapter Three is entitled “Association of wild-type PRRSV detection patterns with 
mortality of MLV-vaccinated growing pig populations.” This study identifies common patterns 
of wild-type PRRSV detection on oral fluids samples collect from MLV-vaccinated growing pig 
populations. Oral fluids were collected every three weeks from batches of pigs originated from 




assesses how the different wild-type PRRSV detection patterns in the field associates with the 
mortality rate of growing pigs. 
Chapter Four is entitled “Comparison of production and economic performance between 
batches of nursery pigs vaccinated with full or half of the dose of attenuated PRRSV vaccine, 
under field conditions.” It describes a retrospective cohort study to compare productivity 
parameters between batches of nursery pigs vaccinated with a full dose versus a half dose of 
PRRS MLV vaccine, following natural exposure to wild-type PRRSV. All batches of nursery 
pigs were originated from PRRSV positive-stable farms and placed in high pig dense areas. 
Regression models were used to compare productivity performance between the two MLV 
vaccination groups. Moreover, a cost-benefit analysis estimated the effect of changes in the 
nursery productivity parameters on profitability. 
Chapter Five is entitled “Comparison of virus detection, productivity, and economic 
performance between batches of growing pigs vaccinated with two doses or one dose of PRRS 
MLV vaccine, under field conditions.” This chapter describes a randomized field trial to 
compare health and productivity performance between growing pig populations vaccinated with 
one dose or two doses of Ingelvac PRRS® MLV vaccine, in commercial swine operations. All 
batches of growing pigs were originated from PRRSV positive farms and were placed in high pig 
dense areas. Six oral fluids samples were collected every three weeks during the growth phase 
from all pig batches and were tested for wild-type PRRSV detection. Regression models were 
used to compare virus detection over time and productivity performance between the two MLV 
vaccination dose groups. Moreover, a cost-benefit analysis was conducted to estimate the 
economic benefit of the second dose of MLV vaccination on the batches of growing pigs, 




Chapter Six provides an overall conclusion to this dissertation by highlighting the 
findings of the four research chapters, proposing the next research steps, and discussing how 
different strategies of PRRS MLV vaccination can help swine producers improve the 
performance of growing pig populations under field conditions.  
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Abstract 
Background: As an attempt to mitigate the losses attributed to porcine reproductive and 
respiratory syndrome virus (PRRSV), some veterinarians have been preventively vaccinating 
sows with PRRS modified-live virus (MLV). This process increases the herd immunity, reduces 
the time-to-stability, and mitigates the negative impact on productivity when the herd becomes 
exposed to wild-type PRRSV. However, the vaccination protocol adds production costs, and 
exposure with MLV might negatively impact subsequent pig productivity. This study aimed to 
describe the changes in productivity on batches of nursery pigs started after the PRRS MLV 
mass sow vaccination events in PRRSV positive-stable breeding herds, compared to batches of 
nursery pigs started previous to mass sow interventions.  
Methods: Three-hundred-thirty-one batches of nursery pigs, originated from 37 different 
PRRSV positive-stable sow farms that were utilizing routine PRRS MLV mass vaccinations on 




classified into five groups, based on the period between the PRRS MLV mass sow vaccination 
date and the nursery start date. Batches placed in the nursery at least six weeks before the mass 
sow vaccinations were classified as the baseline production group. Batches started one to three 
weeks, four to six weeks, seven to nine weeks, and ten to twelve weeks after the mass sow 
vaccinations were classified into post-mass sow vaccination groups 1, 2, 3, and 4, respectively. 
Nursery pig productivity of each post-mass sow vaccination group was assessed and compared to 
the baseline group. 
Results: The nursery mortality rate of all post-mass sow vaccination groups was 
significantly higher than the nursery mortality rate of the baseline group. The average daily gain 
of the post-mass sow vaccination group 1 was significantly higher than that of the baseline 
group. However, no significant difference from the baseline group was detected on average daily 
gain of all other post-mass sow vaccination groups. No significant difference from the baseline 
group was detected in the feed conversion of any of the post-mass sow vaccination groups. 
Based on changes described by the regression models, the post-mass sow vaccination groups had 
lower number of pigs produced, but with a higher weight gain per pig, compared to the baseline 
group. Overall, the ratio of the total weight produced by the four post-mass sow vaccination 
groups over the weight produced by four baseline production groups of the same size was 1.02. 
Conclusions: According to the results of this study, frequently mass vaccination of sows 
with PRRS MLV vaccine with the intent to immunize swine breeding herds to PRRSV was not 
associated with a negative impact on the productivity of the batches of nursery pigs flowing 
downstream. 
 






Porcine reproductive and respiratory syndrome virus (PRRSV) is a pathogen known for 
causing a significant economic impact on the swine industry [1]. In response, some veterinarians 
recommend adopting a preventive PRRS modified-live virus (MLV) mass vaccination program 
on sows as an attempt to mitigate PRRSV-attributed losses when the herd becomes infected with 
the wild-type virus [2, 3], especially for gilts and young sows [4].  
In a study from 2014, breeding herds with a recent history of PRRSV exposure recovered 
the baseline productivity and started producing piglets consistently PRRSV-negative 
significantly sooner after a PRRSV outbreak, compared to herds that were not exposed to the 
virus previous to the outbreak [5]. It is expected that vaccinating the breeding herds with PRRS 
MLV vaccine increases herd immunity, reduces the time-to-stability, and mitigates the impact on 
productivity when the herd becomes exposed to wild-type PRRSV. However, the mass sow 
vaccination process adds production costs, and some have been concerns that the attenuated 
PRRSV from the vaccine might negatively impact sow or piglet productivity especially from 
sows vaccinated on the last third of gestation [6-9].  
Recently, our group reported that adopting routine mass vaccinations with PRRS MLV 
on sows may be a useful strategy to regularly immunize breeding herds to PRRSV with no major 
changes in the sow farm productivity [10]. Although results of that study reported small changes 
in productivity after some mass sow vaccination events, no major impact on weekly data for 
abortion rate, neonatal losses, number of pigs weaned per sow, and wean to first service interval 
were detected within six weeks after applying the mass interventions, compared to six weeks 
previously to the vaccinations. Only an increase of 0.26% of pre-weaning mortality in the second 




the impact that mass vaccinating sows with PRRS MLV vaccine has on subsequent nursery pig 
performance under field conditions. A study conducted in 2007 reported that although morbidity 
during nursery and finishing phase was associated with previous piglet vaccination, no 
significant differences in morbidity of growing pigs were associated with previous sow 
vaccination [11].  
This study sought to describe the changes in productivity performance of batches of 
nursery pigs started after the PRRS MLV mass sow vaccination events in PRRSV positive-stable 
[12] breeding herds, compared to batches started previous to the mass sow interventions. Our 
hypothesis was that vaccinating PRRSV-stable breeding herds with PRRS MLV vaccine does 
not negatively impact the downstream pig performance.  
 
Materials and Methods 
 
Study design 
This was a retrospective cohort study to describe changes in nursery pig productivity 
associated with PRRS MLV mass vaccination events on sows from PRRSV positive-stable 
farms. A farm was considered PRRSV positive-stable when there was no detection of PRRSV 
RNA by RT-qPCR in due-to-wean piglets for at least 90 consecutive days, after being infected 
with wild-type PRRSV [12]. Batches of nursery pigs were selected from 37 sow farms based on 
specific eligibility criteria described below. The start date of each batch of nursery pigs was 
identified, as well as the dates of each PRRS MLV mass sow vaccination from their respective 
sow farm sources. The period between the mass sow vaccination date and the nursery start date 
was measured in weeks. Nursery pig batches were then classified into five groups, based on the 




Regression models were used to describe key productivity parameters for the batches of nursery 
pigs from each post-mass sow vaccination group, compared to batches from the baseline group. 
Moreover, a descriptive productivity model was used to describe how the changes reported by 
the regression models impacted the overall nursery pig productivity of study groups. As this was 




Figure 2-1. Study design. 
 
Settings 
The study population was composed of batches of nursery pigs closed-out between the 
years of 2014 and 2018 from a single production system located in Iowa, USA. The nursery pig 




phase production, weaned with approximately three weeks of age and with approximately eight 
weeks on feed. 
All pig batches were originated from PRRSV positive-stable sow farms adopting 
preventive PRRS MLV mass vaccinations on sows throughout the study period. The mass sow 
vaccination program consisted of exposing all breeding stock (sows and gilts) in the farm to a 
commercial MLV vaccine (as recommended by the manufacturer) regardless of age, parity, or 
stage of production (lactating, gestating, weaned).  
 
Eligibility and exclusion criteria 
The eligibility criteria of pig batches were: a) raised in nursery barns or wean-to-finish 
barns; b) nursery batches closed-out between 01/01/2014 and 12/31/2018; c); all pigs in the batch 
originated from a single PRRSV positive-stable sow farm [12]; and d) implemented at least one 
PRRS MLV mass vaccination during the study period.  
Exclusion criteria of pig batches were: a) source farm reporting outbreak of PRRSV or 
enteric porcine coronaviruses; b) batches including pigs originated from more than one sow 
farm; and c) batches that were started more than 12 weeks after or more than six weeks before a 
mass sow vaccination event in the sow farm. 
 
Study groups and outcomes 
All batches of nursery pigs that were started up to six weeks before the PRRS MLV mass 
sow vaccination events were classified into the baseline production group. Nursery pig batches 
that were started up to twelve weeks after the PRRS MLV mass sow vaccination events were 




Nursery pig mortality was calculated as the total counts of dead pigs during the nursery 
phase relative to the number of pigs that started the nursery pig batch. Nursery pig average daily 
gain was calculated by dividing the net weight produced by the average number of pig days in 
the nursery phase. Nursery pig feed conversion was calculated by dividing the total feed weight 
by the net weight produced in the nursery phase.  
 
Statistical methods 
Statistical analyses were performed using a batch of growing pigs (population) as the 
experimental unit. Linear regression models were built on SAS 9.4 to describe key productivity 
parameters of batches of nursery pigs from each post-mass sow vaccination group, compared to 
batches from the baseline group. Poisson regression was used for mortality rate comparison, by 
modeling the counts of dead pigs and adjusting for the number of pigs started as the offset 
variable. Linear regression was used for average daily gain and feed conversion comparisons. 
The variables season of placement in the nursery, average days on feed, and weight started were 
included in the models as random effects, while sow farm of origin and production flow were 
included as random effects. Seasons were defined as January-March, April-June, July-
September, and October-December of each year during the study period. All statistical analyses 
were done using a significance level of 0.05.  
A fixed time descriptive model was built on Microsoft Excel (version 16.16.26, 
Microsoft Corporation, Redmond, WA) to estimate the overall nursey productivity of batches of 
1,000 pigs from each post-mass sow vaccination group, compared to the baseline group. The 
model used the least square means reported by the regression models to estimate the productivity 
performance of each group. However, changes in productivity of the post-mass sow vaccination 




than 0.25. The overall nursery pig productivity was measured by the total weight of nursery pig 
produced, which was calculated by multiplying the number of pigs produced by the average 
weight gain per pig. The total number of pigs produced was calculated by one minus the 
mortality rate, while the average weight gain per pig was calculated by multiplying the average 
daily gain for a period of 60 days on feed. Additionally, the model described the total weight of 
nursery pig produced of the four post-mass sow vaccination groups, compared to four groups of 
baseline production of the same size. 
 
Results 
The study collected information from 331 eligible nursery pig batches, with average of 62 
days on feed, from 37 sow farms (Table 2-1). There was a total of 481 PRRS MLV mass sow 
vaccinations, with a mean of 2.6 mass sow vaccinations per farm per year. The study excluded 
1675 nursery pig batches due to change in PRRSV status of the sow farm, 894 batches due to 
mixing of pigs originated from different sow farms, and 253 batches because they were started 
more than 12 weeks after or more than 6 weeks before any of the mass vaccinations. 
 
Table 2-1. Baseline demographic data of study groups. 
 Baseline 
group 
Post-mass sow vaccination groups 










Table 2-1. Continued. 
 Baseline 
group 
Post-mass sow vaccination groups 
Characteristics 1 2 3 4 
Average days 
on feed (days)* 
61 ± 15.99 61± 15.60 64 ±15.67 60± 15.64 64 ±15.63 
Number of 
pigs started 
585,739 369,757 404,301 353,005 336,923 
Number of 
batches 
99 61 62 55 54 
*mean ± standard deviation. There was no significant difference between groups in any of the 
baseline demographic characteristics, at alpha 0.05. 
 
The mortality rate of each of the post-mass vaccination groups was significantly higher 
than the baseline group. (Table 2-2).  
 
Table 2-2. Nursery mortality rate of the post-mass sow vaccination groups, compared to the 
baseline group. 
Groups Mortality rate Standard error of the mean P-value 
Baseline group 3.23% 0.0082 - 
Post-mass sow 
vaccination group 1 
4.15% 0.0105 <0.0001 
Post-mass sow 
vaccination group 2 





Table 2-2. Continued.  
Groups Mortality rate Standard error of the mean P-value 
Post-mass sow 
vaccination group 3 
4.63% 0.0117 <0.0001 
Post-mass sow 
vaccination group 4 
4.33% 0.0109 <0.0001 
 
The average daily gain of the post-mass sow vaccination group 1 was significantly higher 
than that of the baseline group. However, there was no significant difference from baseline for 
all other post-mass sow vaccination groups (Table 2-3). No significant differences from the 
baseline group were detected in feed conversion for any of the post-mass sow vaccination groups 
(Table 2-4). 
 
Table 2-3. Average daily gain of the post-mass sow vaccination groups, compared to the 
baseline. 
Groups Average daily gain 
(g/day) 
Standard error of the mean P-value 
Baseline group 347 0.0242 - 
Post-mass sow 
vaccination group 1 
367 0.0246 0.0404 
Post-mass sow 
vaccination group 2 







Table 2-3. Continued. 
Groups Average daily gain 
(g/day) 
Standard error of the mean P-value 
Post-mass sow 
vaccination group 3 
366 0.0248 0.0716 
Post-mass sow 
vaccination group 4 
360 0.0243 0.2341 
 
Table 2-4. Feed conversion of the post-mass sow vaccination groups, compared to the baseline 
group. 
Groups Feed conversion Standard error of the mean P-value 
Baseline group 1.831 0.0430 - 
Post-mass sow 
vaccination group 1 
1.842 0.0454 0.7837 
Post-mass sow 
vaccination group 2 
1.839 0.0455 0.8488 
Post-mass sow 
vaccination group 3 
1.811 0.0469 0.6595 
Post-mass sow 
vaccination group 4 
1.839 0.0444 0.8573 
 
Due to the differences in the mortality rate (with significance level lower than 0.25), the 
total number of pigs produced by the baseline group was higher than that of the post-mass sow 




level lower than 0.25), the average weight gain of post-mass sow vaccination groups 1, 3 and 4 
was higher than that of the baseline group (Table 2-5). The overall nursey productivity, measured 
by the total weight of nursery pig produced, of post-mass sow vaccination groups 1, 3 and 4 was 
higher than the overall nursery productivity of the baseline group. Only the post-mass sow 
vaccination group 2 had lower nursery production, compared to the baseline group.  
 
Table 2-5. Description of overall nursey productivity of each post-mass sow vaccination group 
and the baseline group. 
 Baseline 
group 
Post-mass sow vaccination groups 
 1 2 3 4 
Pigs started  1,000 1,000 1,000 1,000 1,000 
Average days on 
feed 
60 60 60 60 60 
Nursery mortality 3.23% 4.15% 5.15% 4.63% 4.33% 
Pigs produced 968 959 949 954 957 
Average daily gain 
(g/day) 
347 367 347 366 360 
Average weight 
gain (kg/pig) 
20.8 22.0 20.8 22.0 21.6 
Total weight 
produced (kg) 





Overall, the total weight of nursery pig produced by the four post-mass sow vaccination 
groups (representing a period of 12 weeks after the PRRS MLV mass sow vaccinations) was 
82,464 kilos. The total weight of nursery pig produced by four baseline production groups 
(representing a period of 12 weeks with no PRRS MLV mass sow vaccination effect) was 80,591 
kilos. Overall, the ratio of the total weight produced by the four post-mass sow vaccination 
groups over the weight produced by four baseline production groups of the same size was 1.02 
(Table 2-6). 
 
Table 2-6. Description of overall nursey productivity of all four post-mass sow vaccination 
groups and four baseline groups. 
 Baseline 
Production 
Post-mass sow vaccination 
production 
Pigs started 4,000 4,000 
Total weight produced 
(kg) 
80,591 82,464 
Productivity ratio  1.02 
 
Discussion 
This retrospective study sought to describe the impact of mass vaccinating sows from 
PRRSV-stable farms, using PRRS MLV vaccine, on the productivity performance of subsequent 
nursery pig batches. Three-hundred-thirty-one batches of nursery pigs were included in the 
study. All batches originated from 37 different PRRSV positive-stable [12] sow farms, that were 
adopting PRRS MLV mass sow vaccinations during the study period and were not commingling 




the period between the PRRS MLV mass sow vaccination date and the nursery start date. All 
nursery pig batches that started up to six weeks before the PRRS MLV mass sow vaccination 
events were classified into the baseline production group. Nursery pig batches that started one to 
three weeks, four to six weeks, seven to nine weeks, and ten to twelve weeks after the PRRS 
MLV mass sow vaccination events were classified into post-mass sow vaccination groups 1, 2, 3, 
and 4, respectively. 
All post-mass sow vaccination groups had a significantly higher mortality rate compared 
to the baseline group. The average daily gain of the post-mass sow vaccination group 1 was 
significantly higher, compared to the average daily gain of the baseline group, but no significant 
differences were detected for all other post-mass sow vaccination groups. No significant 
differences from baseline in feed conversion were detected in any of the post-mass sow 
vaccination groups. 
Based on the differences in mortality rate with significance level lower than 0.25, the 
production model described that the total number of pigs produced by all post-mass sow 
vaccination groups was lower than the number of pigs produced by the baseline production 
group. However, based on the differences in average daily gain with significance level lower 
than 0.25, the average weight gain per pig by the post-mass sow vaccination groups was higher 
than the baseline group. Overall, the total weight produced by all post-mass sow vaccination 
groups together was similar to the weight produced by four baseline production groups of the 
same size. The only post-mass sow vaccination group with lower total weight produced than the 
baseline was group 2, which may be due to the fact that at the moment of the PRRS MLV mass 





The similar productivity performance of the post-mass sow vaccination groups relative to 
baseline suggests that the PRRS MLV mass sow interventions in PRRSV positive-stable sow 
farms was not associated with a negative impact in the subsequent nursery pig productivity. A 
previous study documented that it was economically beneficial to preventively vaccinate 
breeding herds whenever the expected outbreak frequency was less than every 2.1 years [13]. 
Authors of that study estimated that the impact of mass vaccinating breeding herds with PRRS 
MLV vaccine on growing pig performance was $2.00 per pig. The results of the present study 
suggest that the impact of the MLV mass sow vaccination on the growing pig performance was 
overinterpreted. As the impact of the mass sow intervention described appears to be lower, the 
practice of regularly mass vaccinating sows using PRRS MLV vaccine is expected to be 
beneficial even in herds that break less frequently.   
A study conducted in 2007, reported that although morbidity during the nursery and 
finishing phases was associated with previous pig vaccination, no significant differences in 
morbidity of growing pigs were associated with previous sow vaccination [11]. In a study 
conducted in 2014, authors concluded that piglets from gilts vaccinated at 90 days of gestation 
with a PRRS MLV vaccine had lower average daily gain (from day 0 to 21) and higher pre-
weaning mortality than piglets from non-vaccinated gilts [14]. However, a different study 
conducted in 2016 did not report any differences in birth weight and average daily gain (from 
day 0 to 21) between piglets from gilts vaccinated with PRRS MLV vaccine at 90 days of 
gestation and piglets from non-vaccinated gilts. 
To the best of our knowledge, this is the first epidemiological study with multiple herd-
vaccinations to document associations of PRRS MLV mass vaccinations on sows with the 




of diagnostic information about wild-type PRRSV circulation on the batches of nursery pigs. It is 
important to note that this study included only PRRS positive-stable sow farms and the results 
may not be applicable to pig flows from PRRSV naïve, and/or PRRSV positive-unstable sow 




The nursery mortality rate of the post-mass sow vaccination groups was significantly 
higher than that of the baseline group. Overall, the ratio of the total weight produced by the four 
post-mass sow vaccination groups over the weight produced by four baseline production groups 
of the same size was 1.02. According to the results of this study, mass vaccination of sows with 
PRRS MLV vaccine with the intent to immunize swine breeding herds to PRRSV was not 
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Abstract 
PRRS is a viral disease characterized by increasing reproduction losses in breeding herds 
and worsening performance of growing pigs, which leads to a considerable economic impact. A 
better understanding of the differences in the infection patterns of the virus in growing pig 
batches would help to develop cost-effective surveillance methods and disease control and 
elimination programs. Therefore, field studies documenting growing pig productivity according 
to the patterns of wild-type-PRRSV (wt-PRRSV) detection in the field are needed. This study 
was conducted with the objectives to (1) characterize patterns of wt-PRRSV-1 and wt-PRRSV-2 
RNA detection over time in modified-live virus (MLV)-vaccinated batches of growing pigs 
raised in pig-dense regions of the USA; (2) compare wean-to-finish mortality among batches of 
growing pigs characterized with different patterns of wt-PRRSV-1 and wt-PRRSV-2 detection; 




different patterns of wt-PRRSV-2 detection and vaccinated with two different doses of PRRS 
MLV vaccine.  
Eighty-one batches of growing pigs were originated from PRRSV positive-stable and 
unstable sow farms and vaccinated with two different doses of PRRS MLV vaccine. All batches 
were monitored for wt-PRRSV by testing six oral fluids every three weeks from weaning to 
marketing. Diagnostics were conducted to detect wt-PRRSV-1 and wt-PRRSV-2 RNA by RT-
qPCR testing and ORF-5 region sequencing. K-means clustering analysis was applied to identify 
batches sharing similar patterns of wt-PRRSV detection over time. Regression analyses were 
used to compare mortality among batches of growing pigs characterized with different patterns 
of wt-PRRSV detection over time.  
Thirty-eight percent of batches were detected with wt-PRRSV-1 during the growth phase, 
with three different patterns of detection. Detection of wt-PRRSV-1 was not associated with 
significant increase on mortality. Ninety-one percent of batches were detected with wt-PRRSV-2 
during the growth phase, with four different patterns of detection. Batches originated from 
PRRSV positive-unstable farms had highest mortality rate (p<0.0001) and were characterized as 
Unstable wt-PRRSV-2 detection pattern. Batches characterized with Early wt-PRRSV-2 
detection pattern had higher mortality than batches characterized by Mid, Late and No wt-
PRRSV-2 detection during the growth phase (p<0.0001). Batches with Mid wt-PRRSV-2 
detection had higher mortality than batches characterized with Late wt-PRRSV-2 detection 
(p=0.0124). Mortality rate of batches characterized with Unstable and Early wt-PRRSV-2 
detection patterns was significantly lower when pigs were vaccinated with two doses of PRRS 




Results presented in this study suggested that early wt-PRRSV-2 exposure on pig 
populations was associated with higher wean-to-finish mortality. Additionally, results suggested 
that vaccination with two PRRS MLV doses was associated with lower mortality rate, when 
growing pig populations had early wt-PRRSV-2 exposure. 
 
Keywords: Swine, PRRSV, field epidemiology, growing pigs, two MLV doses. 
 
Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is the causal agent of the 
porcine reproductive and respiratory syndrome (PRRS). Two viral species are described, 
PRRSV-1 (predominant in Europe, also detected in the Americas and Asia) and PRRSV-2 
(predominant in the Americas and Asia) (Zimmerman, 2019). The clinical consequences of the 
PRRSV infection in swine are characterized by increasing reproduction losses in breeding herds 
and worsening performance of growing pigs, which leads to a considerable economic impact 
(Neumann et al., 2005; Holtkamp et al., 2013). Considering that 55% of the economic impact of 
PRRSV in the US swine industry was estimated to occur during the growing phase (Holtkamp et 
al., 2013), there is the need to develop strategies to manage PRRSV infections in growing pig 
populations more effectively. 
A field study conducted in 2012 reported that the frequency of PRRSV-2 RNA detection 
over time on growing pig populations varied considerably among barns from the same 
production site. PRRSV-2 detection ranged from one of ten samplings in one barn to seven of ten 
samplings in another barn (Ramirez et al., 2012). The findings suggest that PRRSV infects and 




differences in the infection patterns of the virus in the field would help to develop cost-effective 
surveillance methods and disease control and elimination programs. 
A study conducted under controlled conditions in 2009 showed that disease was 
markedly more severe and prolonged in 3-week-old piglets infected with PRRSV compared to 
finisher pigs or sows (Klinge et al., 2009). Another controlled experiment reported that pigs that 
received higher doses of PRRSV challenge had higher levels of viremia, higher number of days 
with pyrexia, and lower average daily gain compared to pigs that received lower doses (Haiwick 
et al., 2018). However, field studies documenting growing pig productivity according to the 
patterns of PRRSV detection over time are still needed. 
Based on the literature reporting that PRRSV infects and spreads within growing pig 
populations resulting in different patterns of detection, and that the production impact of PRRSV 
infection is age-dependent, we hypothesize that early detection of wild-type PRRSV (wt-
PRRSV) in batches of growing pigs leads to higher wean-to-finish mortality compared to the 
detection of wt-PRRSV at later stages of production. Therefore, there is a critical need to 
understand the common patterns of wild-type PRRSV detection in batches of growing pigs, and 
how these different patterns are associated with wean-to-finish mortality, under field conditions.  
To fill this knowledge gap, we conducted a prospective epidemiological field study 
focused on growing pig populations vaccinated with PRRS modified-live-virus (MLV) vaccine, 
originated from PRRSV-endemic sow farms, and raised in high pig dense regions of USA with 
the objectives to: (1) characterize patterns of wt-PRRSV-1 and wt-PRRSV-2 RNA detection over 
time; (2) compare wean-to-finish mortality among batches of growing pigs characterized with 




mortality among batches of growing pigs characterized with different patterns of wt-PRRSV-2 
detection and vaccinated with two different doses of PRRS MLV vaccine. 
 
Materials and Methods 
 
Study design 
This multi-source prospective epidemiological field study was conducted from the Fall of 
2017 to Summer of 2019, to characterize wt-PRRSV detection patterns on eligible batches of 
growing pigs in the USA, and assess the association of each detection pattern with wean-to-
finish mortality, under field conditions. Additionally, the study compared the mortality of 
batches of growing pigs vaccinated with two different doses of PRRS MLV vaccine, at each 
detection pattern. 
Batches of growing pigs (n=81) from three different production systems located at 
Southeast (SE) or Midwest (MW) regions of the USA were conveniently selected and included 
in the study based on specific eligibility criteria. The selected batches of growing pigs were 
originated from multiple sow farms (n=9) and flowed onto wean-to-finish, or nursery and 
finishing production flows, and always maintained group integrity from weaning until marketing. 
The batches of growing pigs were randomly selected to receive one dose or two doses of PRRS 
MLV vaccine, by a coin toss. All batches of growing pigs received one dose with 2ml of 
Ingelvac PRRS® MLV vaccine (Boehringer Ingelheim Animal Health USA Inc., Duluth, GA.), 
either around processing or weaning age. The batches allocated into the two doses group 
received the second dose with 2ml of Ingelvac PRRS® MLV vaccine, via intramuscular route, 




Batches of growing pigs were monitored for wt-PRRSV-1 and wt-PRRSV-2 through 
repeated diagnostic testing throughout the wean-to-finish period, which was defined by the phase 
between weaning and marketing (Figure 3-1). The batches were classified based on the 
proportion of oral fluid samples, collected every three weeks, that were positive for wt-PRRSV-1 
or wt-PRRSV-2 RNA by RT-qPCR (quantitative reverse transcription polymerase chain 
reaction) and open reading frame-5 (ORF-5) sequencing. Closeout performance parameters were 
collected from each study population and statistical methods were applied to measure the 
association of observed patterns of wt-PRRSV detection over time on wean-to-finish mortality. 
The Iowa State University institutional animal care and use committee (IACUC) reviewed and 
approved this study protocol on 6/15/2017 (log number 6-17-8538-S). 
 
 
Figure 3-1. Study design. 
 
Eligibility criteria of the study population 
All batches of growing pigs included in the study were selected based on the following 
eligibility criteria: (1) all pigs in the batches originated from PRRSV-positive unstable or 




Veterinarians (AASV) PRRSV classification (Holtkamp et al., 2011); (2) pigs from sow farms of 
different PRRSV status were not commingled (Holtkamp et al., 2011); (3) study pigs were 
previously vaccinated with Ingelvac PRRS® MLV vaccine (Boehringer Ingelheim Animal Health 
USA Inc., Duluth-GA); (4) placed in high pig dense areas and (5) housed in all-in-all-out flows, 
maintaining group integrity from weaning until marketing. For this study, areas having more 
than 185 pig farms per square kilometer, as described by (Alkhamis et al., 2018), were defined as 
pig-dense areas. Additionally, eligibility criteria for production systems included in the study 
included (1) availability to provide eligible batches of growing pigs and (2) availability to 
provide farm staff to collect and ship all the oral fluids as per the study protocol. 
 
Sampling and Diagnostics 
Wild-type PRRSV detection over time was measured by testing oral fluid samples for 
PRRSV RNA by RT- qPCR in all batches of growing pigs throughout the wean-to-finish period. 
The oral fluids collection procedure consisted of allowing pigs to chew on a 5/8-inch cotton rope 
for 20 to 30 minutes and manually harvesting the fluid into a falcon tube (Prickett et al., 2008). 
Sample collection started within one week after weaning (fourth week of age) and was repeated 
every three weeks, for a total of eight collection times per batch during the study period (4, 7, 10, 
13, 16, 19, 22 and 25 weeks of age) (Figure 3-1). At each sampling event, six ropes were 
distributed in the batches using spatially fixed pattern (Rotolo et al., 2017) in the same pens each 
time (Ramirez et al., 2012). Samples were refrigerated after collection and shipped to the Iowa 
State University Veterinary Diagnostic Laboratory (ISU-VDL) for the detection of PRRSV-1 
and PRRSV-2 RNA by RT-qPCR, using previously validated commercial assays.  
If there was at least one PCR-positive sample, the batch was defined as positive for 




value was then submitted for PRRSV ORF-5 sequencing, to differentiate between vaccine-like 
and wild-type virus as described below. The ORF-5 sequencing result was used to represent the 
status of all other PCR-positive samples at the designated sampling event. All PCR-positive 
samples for PRRSV-1 were assumed to be wild-type virus since there was no vaccine against 
this virus used in the study population, nor the source farms. All viruses showing more than 1% 
homology difference than Ingelvac PRRS® MLV vaccine were defined as wt-PRRSV-2. The 
selected cut-off of 99% was due to the shorter interval between sample collections.  
 
Statistical analyses  
Statistical analyses were performed using the batches of growing pigs (populations) as 
the experimental units. Two independent clustering analyses were performed, using the K-means 
analysis in R program, to characterize (1) patterns of wt-PRRSV-1 detection over time and (2) 
patterns of wt-PRRSV-2 detection over time, on batches of growing pigs. The patterns of 
detection included the magnitude and timing of PRRSV RT-qPCR and ORF-5 nucleotide 
sequencing results on the oral fluids samples over time. To determine the optimal number of 
clusters the NbClust function was used (Charrad, 2014). Clustering analysis was performed only 
with batches of growing pigs that originated from PRRSV positive-stable sow farms (Holtkamp 
et al., 2011) and with at least one wild-type PRRSV detection during the study period. 
Generalized linear mixed regression models were built, using “PROC GLIMMIX” in the 
SAS version 9.4 program, to compare differences in wean-to-finish mortality among batches 
characterized by different wt-PRRSV detection patterns. Poisson distribution was used to fit the 
wean-to-finish mortality at each growing pig batch by modeling the counts of dead pigs and 
adjusting for the number of pigs started as the offset variable. The region, the production system 




vaccination were used as fixed effects in the model. The mean mortality with a 95% confidence 
interval was reported for each comparison group. All pairwise comparisons were performed, by 
including “PDIFF” in the “LSMEANS” statement.  As multiplicity, results of wt-PRRSV-2 
patterns were reported by the two different geographical regions of study. The same model was 
used to compare differences in wean-to-finish mortality between batches vaccinated with one 
dose and two doses of PRRSV MLV vaccine, from each wt-PRRSV-2 detection pattern. 
 
Results 
The study included a total of 136,482 growing pigs from 81 batches. The average number 
of pigs started per batch was 1,685, with a higher size of 5,203 pigs and lower size of 633 pigs 
per batch. Seventeen batches of pigs were flowing into wean-to-finish production during the 
growing pig phase, while the other 64 batches were composed of nursery and finishing 
production flows. All pigs from batches included in the study were vaccinated with Ingelvac 
PRRS® MLV vaccine either around 3-5 days of age (n=43) or around 19-21 days of age (n=38). 
Thirty-nine batches of growing pigs were vaccinated with one dose of Ingelvac PRRS® MLV 
vaccine, while 42 batches were vaccinated with two doses of the same vaccine. There were 3,646 
oral fluid samples collected from 634 sampling events. Fourteen (2%) samplings were missed.  
 
PRRSV-1 detection 
For PRRSV-1, a total of 361 (10%) oral fluid samples were RT-qPCR-positive and 3,285 
(90%) tested negative. A total of 93 (15%) samplings events were RT-qPCR-positive and 541 
(85%) were defined as negative, for PRRSV-1. All RT-qPCR-positive cases were assumed to be 




Diagnostic sampling design of this study detected wt-PRRSV-1, at least in one of the 
eight sampling events, in 38% (31/81) of growing pig groups. None of the wt-PRRSV-1 positive 
pig groups were from the Midwest region. In the Southeast region, 56% (31/55) of the groups of 
growing pigs had wt-PRRSV-1 detected, in at least one of the sampling events.  
Three different patterns of wt-PRRSV-1 detection were observed, using the K-means 
clustering method, and were characterized as Early wt-PRRSV-1 detection pattern (n=8), Mid 
wt-PRRSV-1 detection pattern (n=6), and Late wt-PRRSV-1 detection pattern (n=17) (Figure 3-
2). Fifty groups (62%) of growing pigs had no wt-PRRSV-1 detection at any of the sampling 
events and were characterized as No wt-PRRSV-1 detection pattern. 
 
 
Figure 3-2. Patterns of wild-type PRRSV-1 detection over time, based on clustering analysis.  
*=Gray lines are the percentages of detection of each batch at each sampling event. Black dots 
are the averages of the gray lines at each sampling event. Blue lines are the tendency lines (with 





Early wt-PRRSV-1 detection pattern had wean-to-finish mortality of 5.44 % (95% CI 
3.26% – 9.10%), Mid wt-PRRSV-1 detection pattern had mortality of 7.09% (95% CI 3.75% – 
13.42%) and the Late wt-PRRSV-1 detection pattern had mortality of 5.77% (95% CI 3.66% – 
9.09%). The No wt-PRRSV-1 detection pattern had wean-to-finish mortality of 7.34% (95% CI 
4.68% – 11.51%). The wean-to-finish mortality of the No wt-PRRSV-1 detection pattern was 
significantly higher than the mortality of the Early wt-PRRSV-1 detection pattern (p=0.0364) 
and the Late wt-PRRSV-1 detection pattern (p<0.0001). Wean-to-finish mortalities of the 
remaining patterns were not significantly different from each other (Figure 3-3).  
 
 
Figure 3-3. Wean-to-finish mortality by patterns of PRRSV-1 detection (means with standard 
errors). 






For PRRSV-2, there were 2674 (73%) oral fluid samples that were RT-qPCR-positive 
and 972 (27%) tested negative. A total of 559 (88%) sampling events were defined as RT-qPCR-
positive and 75 (12%) tested negative. The ORF-5 sequencing results of the 559 RT-qPCR-
positive samples, representing each sampling event, resulted in 165 (30%) MLV vaccine-like, 
214 (38%) wt-PRRSV-positive, and 180 (32%) could not be sequenced.  
The sampling design of this study detected wt-PRRSV-2, in at least one of the eight 
sampling events, in 91% (74/81) of growing pig groups. In the Southeast region, wild type virus 
was detected, in at least one of the eight sampling events, in 89% (49/55) of growing pig groups, 
while in the Midwest region, 96% (24/25) of groups of growing pigs were positive. 
Twenty-two (27%) groups of growing pigs were not included in the clustering analysis as 
established in the study protocol: 15 (19%) groups, that came from PRRSV positive-unstable 
sow farms (Holtkamp et al., 2011), were allocated in the Unstable wt-PRRSV-2 detection 
pattern. The other seven (9%) groups of growing pigs had no wild-type PRRSV-2 detection at 
the sampling events and were allocated to the No wt-PRRSV-2 detection pattern. The remaining 
groups were assigned to one of three different patterns of wild-type PRRSV-2 detection 
observed, using the K-means clustering method, and were characterized as Early wt-PRRSV-2 
detection pattern (n=18), Mid wt-PRRSV-2 detection pattern (n=30), and Late wt-PRRSV-2 






Figure 3-4. Patterns of wild type PRRSV-2 detection over time, based on clustering analysis, of 
batches that originated from PRRSV stable (Holtkamp et al., 2011) sow farms and with at least 
one wt-PRRSV-2 detection during the growing phase. 
*=Gray lines are the percentages of detection of each batch at each sampling event. Black dots 
are the averages of the gray lines at each sampling event. Blue lines are the tendency lines (with 
95% CI) based on the black dots. 
 
Unstable wt-PRRSV-2 detection pattern had the highest wean-to-finish mortality of 
13.04% (95% CI 7.29% – 23.33%), followed by the Early wt-PRRSV-2 detection pattern, with 
7.67% (95% CI 4.75% – 12.38%), the Mid wt-PRRSV-2 detection pattern, with 5.15% (95% CI 
3.19% – 8.29%), and by the Late wt-PRRSV-2 detection pattern, with 4.24% (95% CI 2.60% – 
6.91%). The No wt-PRRSV-2 detection pattern had wean-to-finish mortality of 4.78% (95% CI 




significantly higher mortality than all other patterns (p<0.0001). Batches characterized with 
Early wt-PRRSV-2 detection pattern had significantly higher mortality than batches 
characterized by Mid, Late and No wt-PRRSV-2 detection during the growth phase (p<0.0001). 
Batches with Mid wt-PRRSV-2 detection had significantly higher mortality than batches 
characterized with Late wt-PRRSV-2 detection (p=0.0124) (Figure 3-5). The mortality results of 
the different patterns of wt-PRRSV-2 detection, by the two different geographical regions of the 
study, are reported in Table 3-1. 
 
 
Figure 3-5. Wean-to-finish mortality by patterns of PRRSV-2 detection over time (means with 
standard errors). 






Table 3-1. Wean-to-finish mortality results of PRRSV-2 detection patterns, reported by the two 







Standard error of 



















































*=Superscript letters indicate statistical differences, with a significance level of 0.05, within each 
region. 
 
When batches were characterized with Unstable and Early wt-PRRSV-2 detection 
patterns, the mortality rate of the batches vaccinated with two doses of PRRS MLV vaccine was 






Figure 3-6. Wean-to-finish mortality by patterns of PRRSV-2 detection over time and by PRRS 
MLV vaccination dose (means with standard errors). 
 
Discussion 
This epidemiological study sought to identify distinct patterns of PRRSV-1 and PRRSV-
2 detection over time in MLV-vaccinated growing pig batches that originated from PRRSV 
endemic sow farms in the USA and were raised in high pig dense areas, and associate it with 
wean-to-finish mortality. All PRRSV-positive batches included were naturally exposed to wt-
PRRSV.  
Overall, more than 90% of the batches of growing pigs had wt-PRRSV-2 detected, in at 
least one of the sampling events, that was unrelated to those previously reported in their 
respective sow source farms. In the Southeast region, wt-PRRSV-2 was detected in 89% of the 




vaccinated growing pigs originated from PRRSV-endemic sow farms and raised in high pig 
dense areas, from Southeast or Midwest regions in the USA, are very likely to be exposed to wt-
PRRSV-2 during the growing phase period. These findings are consistent with results reported 
by another study conducted in 2012 at a growing pig site in Minnesota (USA), where 10 growing 
pig populations were monitored for PRRSV by oral fluid collection every two weeks, and nine 
reported positive results in at least one of the oral fluids sample collections (Ramirez et al., 
2012). 
Overall, 38% of batches of growing pigs tested positive for wt-PRRSV-1. Interestingly, 
none of the batches from Midwest were positive for PRRSV-1. However, 56% of the batches 
belonging to the Southeast region were wt-PRRSV-1 positive in at least one of the sampling 
events. This finding is consistent with data reported by the Swine Disease Reporting System 
(SDRS), suggesting that the frequency of detection of PRRSV-1 in the USA is more 
concentrated in Southeast region (Trevisan et al., 2019). 
Results reported in this study also suggest that the earlier the wt-PRRSV-2 is detected the 
higher is the wean-to-finish mortality in those batches of growing pigs. A controlled trial from 
2009 also showed that the consequences of PRRSV infection were age-dependent (Klinge et al., 
2009). The disease was markedly more severe and prolonged in 3-week-old piglets compared to 
finisher pigs or sows. Investigators concluded that this effect was, perhaps, due to a well-
developed innate immune response developed by the older animals. Another study has concluded 
that regardless of the virus strain, young pigs were more susceptible to infection than older pigs 
(van der Linden et al., 2003). Results showed more viremic pigs and more pigs shedding the 
virus in the younger group. A study conducted under controlled conditions observed similar 




based on the results of this study, the detection of wt-PRRSV-1 on batches of growing pigs from 
the USA does not appear to be associated with changes in wean-to-finish mortality. In general, 
PRRSV-1 is considered less virulent and causes less severe respiratory disease in growing pigs 
compared to PRRSV-2 (Halbur et al., 1996; Martínez-Lobo et al., 2011; Han et al., 2013). The 
detection of wt-PRRSV-1 and wt-PRRSV-2 on the batches of growing pigs simultaneously was 
not associated with any significant increase on the wean-to-finish mortality rate. 
Results from this study suggest that the consequences of PRRSV challenge in growing 
pigs are more severe in batches infected early in the growing phase. Based on the results, it may 
be beneficial to focus on improving biosecurity practices in the early phases of production to 
help reduce the infection pressure and potentially decrease losses associated with PRRSV 
infection as well. Moreover, results reported that when pig populations were infected with wt-
PRRSV-2 at early stages of life, the wean-to-finish mortality rate was significantly lower on 
batches with pigs vaccinated with two doses of PRRS MLV vaccine than on batches with pigs 
vaccinated with only one dose. 
The fact that results were based on ORF-5 nucleotide sequencing (not whole genome 
sequencing) of only 1 RT-qPCR positive sample (not all the six samples) at each sampling event, 
is a limitation of this study. In addition, this study did not include data on other pathogens that 
may have influenced the outcome. Our study also did not provide sufficient evidence to confirm 
if wt-PRRSV detections originated from sow farms, virus mutations, or lateral introductions.  
 
Conclusions 
Ninety-one percent (74/81) of batches of growing pigs placed in pig-dense areas in the 
USA were found to be positive for wt-PRRSV-2 at least once, despite being vaccinated with 




populations was associated with higher wean-to-finish mortality. This association suggests the 
potential benefit of improving bio-exclusion, bio-management, and bio-containment practices, 
especially on breeding herds and nursery batches, to reduce wt-PRRSV activity and improve 
performance, of growing pig populations. Additionally, results described that vaccination with 
two PRRS MLV doses was associated with lower mortality rate, when growing pig populations 
had early wt-PRRSV-2 exposure. 
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Summary 
Objectives: The study objective was to compare productivity and economic performance 
between batches of nursery pigs vaccinated with a full dose of PRRS MLV vaccine and batches 
vaccinated with a half dose of the same vaccine.  
Materials and Methods: The study population was composed of batches of nursery pigs 
originated from three different commercial sow farms. Pigs received one dose of PRRS MLV 
vaccine at the full label rate of 2 ml at three days of age or a half dose with 1 ml of the same 
vaccine at the same age. All batches of nursery pigs originated from PRRSV positive-stable sow 
farms and were placed in high pig density areas. Key productivity performance indicators were 
compared between the full dose and the half dose groups. Moreover, an economic analysis 





Results: The full MLV dose group had a significantly higher average daily gain than the 
half MLV dose group (P=0.0054). No significant differences were detected in the mortality rate 
(P=0.1421) and the feed conversion (P=0.6746) between the full and the half MLV dose groups. 
Based on changes in productivity detected, vaccination with a full MLV dose was economically 
beneficial, compared to using only half of the labeled dose, with a benefit-cost ratio of 2.16.  
Implications: Results suggests that the vaccination of pigs with one full dose of PRRS 
MLV vaccine is associated with improved nursery pig productivity and nursery pig profitability, 
compared to the vaccination with only half dose of the same vaccine. 
 
Keywords: Swine, PRRSV, vaccination, half MLV dose, field epidemiology. 
 
Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a swine-specific 
pathogen that causes reproductive failures and respiratory disease.1 The clinical consequences of 
virus infection translate into a significant economic impact on swine production.2 To minimize 
losses associated with PRRSV infection in the field, the swine industry has been developing 
strategies to control and eliminate the virus from pig populations.3  
PRRS modified-live virus (MLV) vaccination is used worldwide to immunize sow and 
pigs against wild-type PRRSV.4 A study published in 2014 reported that swine breeding herds 
with a recent history of PRRSV exposure had lower production losses due to PRRSV outbreaks 
compared to herds with no prior immunity.5 In response, there is an increasing number of 
breeding herds regularly immunizing their sows with PRRS MLV products.6 
The efficacy of PRRS MLV vaccination to reduce PRRSV-associated production losses 




rate significantly reduced the clinical consequences of wild-type PRRSV challenge compared to 
non-vaccinated pigs.7-13  
Some veterinarians have been experimenting with partial PRRS MLV dosing strategies 
for growing pigs to reduce production costs. Statistical process control analysis was used in a 
previous study to show that groups of growing pigs immunized with a full dose of PRRS MLV 
vaccine had a lower wean-to-finish mortality rate compared to prior groups that were vaccinated 
with a half dose of the same product.14 However, there is the need for more scientific information 
describing the productivity and profitability of growing pigs vaccinated with a full MLV dose, 
compared to pigs vaccinated with a half MLV dosing strategy. 
This field study was conducted with the objectives to compare key nursery performance 
indicators and economic performance between batches of nursery pigs vaccinated with a full 
labeled dose of PRRS MLV vaccine and batches vaccinated with a half dose of the same 
vaccine, following natural exposure to field circulating wild-type PRRSV. We hypothesized that 
the vaccination with a full MLV dose would be associated with a better productivity performance 
than the vaccination with a half MLV dose, as demonstrated by lower mortality rate, higher 
average daily gain, and lower feed conversion. 
 
Materials and Methods 
 
Study design 
This was a retrospective cohort study conducted under field conditions. The study 
population was composed of batches of nursery pigs originated from three different commercial 
sow farms. In order to be eligible for a parallel randomized field experimental study, pigs from 




following an alternation pattern. The study batches were vaccinated with either a full dose or a 
half dose of a commercial PRRSV MLV vaccine. Two blocks of nursery pig batches weaned 
within four to eight weeks were created for each sow farm (Figure 4-1). The first half of each 
block included weeks with batches vaccinated with one vaccination protocol, followed by the 
same number of weeks including batches vaccinated with the other vaccination protocol. The 
duration of the blocks (in weeks) was defined based on the time to fill an all-in-all-out nursery 
site operation with pigs of the same vaccination protocol. Key productivity performance 
indicators were compared between the full MLV dose and the half MLV dose groups using 
regression analyses. Moreover, a benefit-cost ratio analysis evaluated the financial impact of the 










The study population was composed of batches of nursery pigs flowing from three 
PRRSV positive-stable15 breeding herds of a USA production system. Batches of nursery pigs 
were defined as production sites composed of pigs weaned at approximately three weeks of age 
and raised until the end of the nursery phase, with approximately seven weeks of placement.  
All batches of nursery pigs included in this study were selected based on the following 
eligibility criteria: (1) previously vaccinated with a single half dose or with a single full dose of 
PRRS MLV vaccine, (2) placed between summer of 2017 and winter of 2018, (3) pigs from 
different sow farms were not commingled; (4) raised in nursery production facilities with all-in-
all-out flow by site, and (5) located in regions of a relatively high density of pig sites, measured 
as having more than 185 pigs/km2.16 As this study was an observational cohort study using 
retrospective data, no animal care and use approval was required. 
 
Variables 
All pigs from the full MLV dose group received a single intramuscular injection with 2 
ml of a commercial PRRS MLV vaccine between two and four days of age. The pigs from the 
half MLV dose group received a single intramuscular injection with 1ml of the same vaccine at 
the same age.  
Response variables were collected from nursery summary reports provided by producers. 
Nursery pig mortality was calculated as the number of dead pigs during the nursery phase 
divided by the total number of pigs placed per batch. Nursery pig average daily gain (ADG) was 




feed, without dead weight. Nursery feed conversion (FC) was calculated by total feed weight 
divided by the net weight produced, without dead weight.   
 
Statistical Analyses 
Statistical analyses were performed using a batch of nursery pigs (population) as the 
experimental units. The sample size implemented in this study was estimated to detect minimum 
differences of 0.6% (3.6% to 3%) on the mortality rate, assuming a Poisson distribution with 
power of 80%, 95% confidence level, and ratio of sample sizes (number of pigs placed in the full 
dose group/number of pigs placed in the half dose group) of 0.5. The sample size also allowed 
detecting a minimum difference of 0.030 kg on the average daily gain, assuming Normal 
distribution with a variance of 0.001, power of 80%, 95% confidence level, and ratio of sample 
sizes (number of batches in the full dose group/number of batches in the half dose group) of 0.5. 
Additionally, the sample size allowed detecting a minimum difference of 0.113 on the feed 
conversion, assuming Normal distribution with a variance of 0.01, power of 80% and 95% 
confidence level and the ratio of sample sizes (number of batches in the full dose group/number 
of batches in the half dose group) of 0.5.  
Regression models were used to compare key productivity parameters between the full 
MLV dose group and the half MLV dose group. Poisson regression model was built on SAS 9.4 
to model the mortality rate in each nursery pig batch, as the counts of dead pigs adjusted by the 
number of pigs started as the offset variable. Rate ratios with 95% confidence intervals were 
reported. Linear regression models were built on SAS 9.4 to model the average daily gain and 
the feed conversion on each nursery pig batch. Mean differences with 95% confidence intervals 
were reported. The variables sow farm and block were included in the statistical models as 




A relative benefit-cost analysis was conducted to compare the economic performance 
during the nursery phase between the full MLV dose group and the half MLV dose group. A 
production and economic model was built in Microsoft Excel (version 16.16.26, Microsoft 
Corporation, Redmond, WA) to estimate the impact that the changes in the nursery productivity 
parameters described by the regression models have in economic terms. The economic benefit of 
using the full MLV dose vaccination was calculated by the difference in net profit between a 
batch of 10,000 pigs vaccinated with the full MLV dose and a batch of the same size vaccinated 
with the half MLV dose. The direct economic cost of using the full MLV dose vaccination was 
calculated by the difference in the costs to vaccinate a batch of 10,000 pigs using a full MLV 
dose and a batch of the same size using a half MLV dose. The ratio of the economic benefit over 
the direct economic cost of the full MLV dose vaccination was reported as a benefit-cost ratio. 
The full MLV vaccination dose was considered economically beneficial, over the half MLV 
vaccination dose, if the benefit-cost ratio reported was greater than 1. 
The production and economic model used the least square means reported by the 
regression models to estimate the differences in nursery productivity between pigs vaccinated 
with a full and with a half MLV dose. However, numerical differences were only included if the 
significance level was lower than 0.25. The net profit of full and half MLV dose groups was 
calculated based on the differences of revenue and production costs. The revenue of full and half 
MLV dose groups was calculated based on the total weight of nursery pig produced, with a 
“fixed time” of 48 days on feed. The feeder pig price was calculated based on $54.91 for 18.14 
kilos (based on the monthly average sales value in dollars from January of 2018 to December of 
2018 in http://www2.econ.iastate.edu/estimated-returns/) plus a marginal feeder pig price of 




between the sliding value of $0.88 (reported by USDA in 
https://www.ams.usda.gov/mnreports/nw_ls255.txt) and $2.31, which is the average weight per 
kilo calculated for a pig of 27.22 kilos, based on the price of $62.89 ($54.91 for 18.14 
kilos+$0.88*9.07 kilos). Production costs were calculated based on the fixed cost of $1.6/pig, 
weaned pig cost of $40.02/pig, diet cost of $0.44/kilo of feed, and other variable costs of 
$8.19/pig (based on the monthly average sales value in dollars from January of 2018 to 
December of 2018 in http://www2.econ.iastate.edu/estimated-returns/). The vaccination costs 
were calculated based on $1.00 for a full vaccine dose and $0.10 for vaccination labor per pig 
(Table 4-1). 
 
Table 4-1. Production and economic parameters of half MLV dose group and full MLV dose 
group. 




Productivity   
Pigs placed (pigs/group) 10,000 10,000 
Average days on feed (days/pigs) 48.00 48.00 
Average start weight (kg/pig) 5.44 5.44 
Nursery mortality (% of deaths) 2.81% 3.09% 
Nursery ADG (kg/day) 0.377 0.405 
Nursery FC (kg feed/kg gain) 1.516 1.516 
Revenue and production costs   





Table 4-1. Continued. 




Fixed cost ($/pig) $1.60 $1.60 
Weaned pig cost ($/pig) $40.02 $40.02 
Feed cost ($/kg of feed) $0.44 $0.44 
Other variable cost ($/pig) $8.19 $8.19 
MLV vaccination costs   
Vaccine cost ($/dose) $0.50 $1.00 
Vaccination cost ($/pig) $0.10 $0.10 
 
A sensitivity analysis was conducted using the Data Table function on Microsoft Excel 
(version 16.16.26, Microsoft Corporation, Redmond, WA) to describe how the differences in the 
vaccination costs and in the feeder pig prices would change the benefit-cost ratio of the full MLV 
vaccination dose. The changes in prices that were applied in the sensitivity analysis were based 
on changes of $0.3575 in the marginal feeder pig price and on changes of $0.20 in the cost of the 
full vaccination dose.  
 
Results 
The study included a total of 33,745 pigs. There were 20 nursery pig batches totaling 
22,442 pigs that were vaccinated with the half MLV dose, and 10 nursery pig batches totaling 
11,303 pigs that were vaccinated with the full MLV dose (Table 4-2). The number of nursery pig 
batches on the full MLV dose group and on the half MLV dose group within each block is 





Figure 4-2. Overview of sample size for all blocks at each sow farm. 
 
Table 4-2. Baseline demographic characteristics of half MLV dose group and full MLV dose 
group. 
Characteristics Half MLV dose group* Full MLV dose group* 












Batches started 20 10 





Productivity performance comparison 
The half MLV dose group had a non-significantly lower mortality rate than the full MLV 
dose group (P=0.1421). The mortality rate ratio was 0.91 (95% CI: 0.79 – 1.04) (Figure 4-3). 
The average daily gain of the half MLV dose group was significantly higher than the average 
daily gain of the full MLV dose group (P=0.0054). The average daily gain difference was -0.03 
(95% CI: -0.05 – -0.01) (Figure 4-4). The half MLV dose group had a non-significantly higher 
feed conversion than the full MLV dose group (P=0.6746). The feed conversion difference was 
0.02 (95% CI: -0.07 – 0.14) (Figure 4-5). 
 
 
Figure 4-3. Comparison of nursery mortality rate between batches of pigs vaccinated with a full 
PRRS MLV vaccine dose and batches vaccinated with a half dose of the same vaccine (means 






Figure 4-4. Comparison of nursery average daily gain between batches of pigs vaccinated with a 
full PRRS MLV vaccine dose and batches vaccinated with a half dose of the same vaccine 
(means with standard errors). 
 
 
Figure 4-5. Comparison of nursery feed conversion between batches of pigs vaccinated with a 
full PRRS MLV vaccine dose and batches vaccinated with a half dose of the same vaccine 





Economic performance comparison 
Based on the changes in productivity reported by the regression models, the net profit of 
the full MLV dose group was $10,823 higher than the net profit of the half MLV dose group. 
The vaccination costs of the full MLV dose group were $5,000 higher than the vaccination costs 
of the half MLV dose group. As the economic benefit was higher than the direct economic cost, 
the vaccination with a full MLV dose was considered economically beneficial, with a benefit-
cost ratio of 2.16 (Table 4-3).  
 
Table 4-3. Economic performance comparison between half MLV dose group and full MLV 
dose group. 
Economics Half MLV 
dose group 
Full MLV  
dose group 
Difference 
Productivity    
Average final weight (kg/pig) 23.54 24.90 1.36 
Total weight produced (kg/group) 228,774 241,328 12,554 
Feed fed per group (kg of feed/group) 266,642 285,886 19,262 
Revenue and production costs    
Revenue ($/group) $617,303 $636,602 $19,299 
Fixed costs ($/group) $16,000 $16,000 $00.00 
Weaned pig costs ($/group) $400,200 $400,200 $00.00 
Feed costs ($/group) $117.321 $125,797 $8,476 




Table 4-3. Continued.  
Economics Half MLV 
dose group 
Full MLV  
dose group 
Difference 
Net profit ($/group) $1,881 $12,705 $10,823 
Vaccination costs     
Vaccine and labor costs ($/group) $6,000 $11,000 $5,000 
Benefit-cost ratio - - 2.16 
 
Differences in the benefit-cost ratio of the full MLV vaccination with varying feeder pig 
prices and varying vaccination costs are described in Figure 4-6.    
 
 
Figure 4-6. Sensitivity analysis of the benefit-cost ratio of the full MLV vaccination, with 
varying feeder pig prices and varying vaccination costs. 
 
Discussion 
This retrospective cohort study sought to describe productivity and economic 
performance between batches of nursery pigs vaccinated with a full dose of PRRS MLV vaccine 




from 30 nursery pig batches from three different sow farms were used. A blocking design was 
used to match consecutive batches of nursery pigs flowing from the same sow farms vaccinated 
with the two different MLV vaccination doses. All nursery pig batches included in the study 
originated from PRRSV positive-stable sow farms15 and raised in areas of a high chance of 
exposure to field circulating wild-type PRRSV due to high pig density.  
A study conducted in 2016 with 463 groups of growing pigs experiencing higher than 
expected mortality reported a reduction in wean-to-finish mortality on groups of pigs vaccinated 
with a full PRRSV MLV dose, compared to prior groups that received only half of the MLV 
vaccine dose (from 5.69% to 4.12%).14 Results of this present study showed a significant 
increase in the average daily gain of batches of nursery pigs vaccinated with a full MLV dose, 
compared to batches that were vaccinated with only a half dose of the vaccine. However, no 
significant differences were detected in the mortality rate or feed conversion between study 
groups. The study sample size only had 32% of power to detect statistical significance on the 
observed difference in mortality rate and 6% of power to detect statistical significance on the 
observed difference in feed conversion between the full MLV dose group and the half MLV dose 
group. 
Based on the changes reported by the regression models (with a p-value lower than 0.25), 
the economic analysis presented in this study suggested that it was economically beneficial to 
use a full MLV vaccination dose to immunize pigs, compared to using only half of the dose. The 
model described that the improvement in the nursery net profit (economic benefit) of the full 
MLV dose group represented 216% of the increase in the vaccination costs (direct economic 
cost). However, the benefit-cost ratio was very sensitive for changes in the prices applied in the 




were lower than $2.27 for a full dose or when the marginal feeder pig price was higher than 
$1.15/kilo.  
Based on the production and economic model described, the total weight of nursery pig 
produced was higher on the full MLV dose group, with a difference of 1.36 kg per pig. This 
difference in weight increased the revenue by $19,299 per 10,000 pigs for the full MLV dose 
group compared to the half MLV dose group. The batches vaccinated with the full MLV dose 
also had a higher feed cost to produce the extra weight, which resulted in an increase of $8,476 
in the total production costs. Overall, the net profit of the full MLV dose group was higher than 
the net profit of the half MLV dose group by $10,823. This improvement in net profit was 
greater than the increase in vaccination costs, which was $5,000, making the full MLV 
vaccination dose economically beneficial.  
One limitation of this study was that the vaccination protocol allocated to pig batches 
followed an alternation pattern and not a randomized process. Sow farms were alternating the 
vaccination protocol of pigs for a specific number of weeks and not randomly allocating the 
vaccination to pig batches. However, no significant changes were found on the baseline 
demographic parameters between both vaccination groups. Another limitation of this study was 
the lack of diagnostic monitoring to confirm that all batches were challenged with wild-type 
PRRSV during the nursery phase. One possible reason for not detecting significant 
improvements of the mortality rate and feed conversion on the full MLV dose group, compared 
to the half MLV dose group, is that pig batches might not have faced enough wild-type PRRSV 





The vaccination of pigs with one full dose of PRRS MLV vaccine was associated with a 
significantly higher average daily gain compared to the vaccination with only half dose of the 
same vaccine. 
Based on changes in productivity described, the vaccination of pigs with a full MLV dose 
was associated with an improved economic performance compared to the vaccination with a half 
MLV dose, with a benefit-cost ratio of 2.16. 
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Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) causes a significant 
economic impact on swine production. It has been demonstrated that PRRS modified-live virus 
(MLV) vaccination of pigs, with one full dose, significantly reduces clinical consequences of 
wild-type PRRSV infection compared to non-vaccinates. However, there is limited information 
about the effect that two doses of PRRSV MLV vaccine have on the performance of growing 
pigs, compared to vaccination with a single dose. This study was conducted with the objectives 
to compare (a) the wild-type PRRSV detection in oral fluids over time, (b) key closeout 




vaccinated with two doses of Ingelvac PRRS® MLV vaccine and batches vaccinated with a 
single dose of the same vaccine.  
This randomized field trial included 15 batches of growing pigs from PRRSV positive-
unstable sow farms and 66 batches from PRRSV positive-stable sow farms, according to the 
American association of swine veterinarians’ terminology. All pig batches received the first 
vaccination either around processing or weaning age. Batches allocated in the two doses group 
received the second vaccination three to four weeks after the first vaccination. The pig batches 
were monitored for PRRSV detection over time. Six oral fluids samples were collected in three 
weeks intervals and were tested for wild-type PRRSV-2 RNA by RT-qPCR and open reading 
frame 5 (ORF)-5 sequencing. Regression models were used to compare wild-type PRRSV 
detection dynamics on oral fluids samples and to compare key closeout performance indicators 
between one dose group and two doses group. Additionally, a benefit-cost ratio analysis 
compared economic performance between one dose and two doses groups. 
The proportion of wild-type PRRSV detection on oral fluids samples and the log counts 
of viral RNA per ml of oral fluids from the two doses group was lower than the one dose group 
on batches originated from PRRSV positive-stable sow farms, with a risk ratio of 1.24 and a rate 
ratio of 1.17, respectively. The two doses group had a significantly lower mortality rate than the 
one dose group, with a rate ratio of 1.21. The effect size increased on batches originated from 
PRRSV positive-unstable sow farms, and on batches with higher frequency and diversity of 
wild-type PRRSV detection during the growth phase. No differences in growth performance 
were detected between two doses and one dose groups. The second MLV vaccination dose had a 




benefit-cost ratio was 4.45, and for batches originated from PRRSV positive-stable farms, the 
benefit-cost ratio was 0.45. 
Under study conditions, vaccinating growing pig batches with two doses of PRRS MLV 
vaccine was a useful strategy to immunize growing pigs against PRRSV, lowering the wild-type 
PRRSV detection, lowering mortality rate, and increasing profitability, compared to groups of 
growing pigs that received a single dose of the same vaccine. 
 
Keywords: PRRSV, vaccination, two MLV doses, growing pigs, field epidemiology. 
 
Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) infects pig populations, 
causing reproductive disorders and systemic disease [1]. The agent has been present in the global 
swine industry for over 30 years and still causes significant economic impact to swine production 
[2, 3]. Based on Holtkamp et al., 55% of this impact is on the growing pig phase [3]. 
Over the last years, the swine industry has been developing strategies to mitigate the 
consequences of virus infection. Such practices consist of creating and improving population-
based methods for PRRSV diagnostics in swine [4-12] and developing cost-effective 
immunization strategies for sows and pigs [13-18]. 
It has been demonstrated that PRRS modified-live virus (MLV) vaccination with one full 
dose significantly reduces clinical consequences of PRRSV challenge compared to non-
vaccinated pigs [19-25]. Aiming to further improve the protection against heterologous field 
viruses, researchers worldwide have developed new PRRSV immunization strategies [26-34].  
In the field, the application of two PRRS MLV vaccine doses, thirty days apart, 




there is limited information on how this strategy of vaccinating growing pigs with two PRRS 
MLV vaccine doses improves the protection against field viruses compared to vaccination with a 
single PRRSV MLV vaccine dose. 
This study was conducted with the objectives to compare (1) the wild-type PRRSV 
detection in oral fluids over time, (2) key closeout productivity indicators, and (3) economic 
performance between batches of growing pigs vaccinated with two doses of Ingelvac PRRS® 
MLV vaccine and batches vaccinated with a single dose of the same vaccine. We hypothesize 
that the second dose of PRRSV MLV vaccine significantly reduces wild-type viral detection and 
improves the productivity performance of growing pig populations subsequently naturally 
challenged with wild-type PRRSV. 
 
Materials and Methods 
 
Study design 
This was a multi-source, 1-dose-matched randomized field trial, conducted from the Fall 
of 2017 to the Summer of 2019, to compare virus detection, productivity, and economic 
performance of growing pig populations immunized with two different protocols of Ingelvac 
PRRS® MLV vaccination, in commercial swine operations (Figure 5-1). Nine sow farms, from 
three production systems, were conveniently selected to participate and their subsequent growing 
pig batches were included in the study. A growing pig batch was defined as cohort of pigs placed 
in all-in all-out growing pig operations from wean to market. A randomized blocking design was 
used to allocate the two vaccination protocols to the batches of growing pigs. One block with 
sixteen batches of growing pigs from each sow farm of the production system A was created, 




of growing pigs from each sow farm. A fair coin was tossed to determine the vaccination 
protocol of the first half of the groups in each block. The second half of the groups automatically 
received the other vaccination protocol.  
 
 
Figure 5-1. Study design. 
 
All the randomization and blocking process was done by the principal investigator of the 
study (CAAM) before the study began. Blinding of those administering the interventions and the 
caregivers was not possible, as the research was done in field conditions, and caregivers were the 
ones administering the vaccination events. However, people assessing the outcomes were 
unaware of the vaccination protocol that each experimental unit received. The Iowa State 
University institutional animal care and use committee (IACUC) reviewed and approved this 





Eligibility and exclusion criteria of the study population 
All batches of growing pigs included in the study were selected based on the following 
eligibility criteria: (1) all pigs in the batch originated from PRRSV positive-unstable or PRRSV 
positive-stable sow farms according to the 2011 American Association of Swine Veterinarians 
(AASV) PRRSV classification [36]; (2) pigs from sow farms of different PRRSV status were not 
commingled; (3) placed in high pig dense areas, defined as the region having more than 185 
pigs/km2 [37], (4) housed in all-in-all-out flows, and (5) group integrity maintained from 
weaning until marketing. Additionally, eligibility criteria for production systems included (1) 
ability to provide eligible batches of growing pigs and (2) availability to provide farm staff to 
collect and ship all the oral fluids as per the study protocol. 
The exclusion criteria of batches of growing pigs included (1) reports of non-PRRS 
disease outbreaks of agents that impact the closeout performance indicators of experimental 
units, including porcine epidemic diarrhea virus (PEDV) and Actinobacillus pleuropneumoniae 
(App) outbreaks, and (2) report of non-infectious events or conditions that impact closeout 
performance indicators of pig batches.  
 
 Vaccination program 
All 81 batches of growing pigs received a dose of 2ml of Ingelvac PRRS® MLV vaccine 
(Boehringer Ingelheim Animal Health USA Inc., Duluth, GA.) via the intramuscular route, either 
around processing age (3-5 days of age) or around weaning age (19-21 days of age). Batches 
allocated in the two doses group received a second dose of 2ml of Ingelvac PRRS® MLV 
vaccine, via intramuscular route, approximately three to four weeks from the first vaccination.  
Seven sow farms were PRRSV positive-stable and two sow farms, both from production 




and C received the first vaccine dose at weaning age, while batches of growing pigs from 
production system B received the first vaccine dose at processing age. The blocking design 
matched batches of pigs from one dose and two doses groups by same sow farms and by the 
timing of the first vaccination dose.  
 
Diagnostic monitoring 
All 81 batches of growing pigs included in the analysis were monitored for wild-type 
PRRSV detection during the wean-to-finish phase, by testing oral fluids. Six cotton ropes were 
spatially distributed in each batch of growing pigs in three weeks intervals, totaling eight 
sampling events between weaning and marketing. All samples were sent to Iowa State University 
Veterinary Diagnostic Laboratory and tested individually to detect PRRSV-2 RNA by RT-qPCR 
(quantitative reverse transcription polymerase chain reaction), which reported Cycle threshold 
(Ct) values, and PRRSV RNA copies/ml. If at least one of the six oral fluids samples were RT-
qPCR positive, the sample with the lowest Ct value was submitted for PRRSV open reading 
frame 5 (ORF)-5 genetic sequencing. Sampling events with ORF-5 sequencing results reporting 
more than 1% of genetic differences from the ORF-5 of the Ingelvac PRRS® MLV vaccine were 
defined as wild-type PRRSV. The RFLP (restriction fragment length polymorphism) cut pattern 
of each sampling event was also collected from the diagnostic report. The frequency of wild-type 
PRRSV detection was measured by the number of positive wild-type PRRSV sampling events at 
each growing pig batch. The diversity of wild-type PRRSV detection was measured by the 






Statistical analyses were performed using batches of growing pigs (populations) as the 
experimental units. The sample size of 53,249 pigs was calculated to detect minimum differences 
of 0.5% (4.5% to 4%) on the mortality rate between one dose and two doses groups. The 
calculation assumed a Poisson distribution, with 80% of power, 95% confidence level and ratio 
of sample sizes of 1. In order to achieve the sample size, 81 groups containing at least 660 
growing pigs were included in the study. 
Regression models were used to compare wild-type PRRSV RNA detection on oral fluids 
samples between two doses and one dose groups. Binomial regression models were built on SAS 
9.4 (SAS Institute, Inc., Cary, NC) to model the proportion of wild-type PRRSV detection on 
oral fluids samples at each sampling event. The proportion of wild-type PRRSV detection was 
calculated by dividing the number of PCR-positive oral fluids samples by six, only for sampling 
events defined as wild-type PRRSV. The P-values and the risk ratios with 95% confidence 
intervals were reported. Poisson regression models were built on SAS 9.4 to model the log 
counts of viral RNA per ml of oral fluids at each sampling event. The counts of genetic copies of 
PRRSV RNA per ml of oral fluids was assessed only for oral fluids samples from sampling 
events defined as wild-type PRRSV. The log counts of viral RNA per ml of oral fluids at each 
sampling event was calculated by log (sum of the counts of genetic copies of PRRSV RNA per 
ml of oral fluids of all positive samples + 1). The P-values and the rate ratios with 95% 
confidence intervals were reported. 
Linear mixed regression models were used to compare key closeout productivity 
indicators between two doses and one dose groups. Poisson regression models were built on SAS 
9.4 to model the mortality rate on each growing pig batch, by the counts of dead pigs adjusted by 




confidence intervals were reported. Linear regression models were built on SAS 9.4 to model 
average daily gain and feed conversion. The P-values and the mean differences with 95% 
confidence intervals were reported. PRRSV status of the sow farm and timing of the vaccination 
were used as fixed effects in the models. Region, system, sow farm, and blocks were used as 
random effects in the models. All statistical analyses were done using significance level of 0.05. 
A benefit-cost ratio analysis was used to compare economic performance between two 
doses and one dose groups. A production-economic model was built on Microsoft Excel (version 
16.16.26, Microsoft Corporation, Redmond, WA) to estimate the effect that the changes in the 
productivity parameters described by the regression models have in economic terms. The model 
calculated the economic benefit of adding the second MLV vaccination dose to batches of 
growing pigs by the ratio of the difference in net profit over the difference in vaccination costs, 
between two doses and one dose groups. 
The model used the least square means reported by the regression models to estimate the 
differences in productivity between batches of 10,000 growing pigs from one dose and two doses 
groups. The numerical differences were only included if the significance level was lower than 
0.25. The revenue by group was calculated based on the total weight of market pig produced, 
with market pig prices of $1.14 per kg ($140,00 for a 122 kg pig). Production costs by group 
were calculated based on fixed costs of $11.79/pig, weaned pig costs of $42.86/pig, diet costs of 
$0.24/kg of feed, and variable costs of $19.75/pig (Table 5-1). The net profit of one dose and two 
doses groups were calculated based on the difference of revenue and production costs. The 
vaccination costs of one dose and two doses groups were calculated based on the price of $1,00 
per vaccine dose and $0.10 per vaccination labor. The ratio of the difference in net profit over 




benefit-cost ratio. The second MLV vaccination dose was considered economically beneficial if 
the benefit-cost ratio was greater than 1, which means that the benefit of using the second MLV 
vaccination dose was higher than the cost to implement the second MLV vaccination dose. 
 
Table 5-1. Productivity and economic parameters of one dose and two doses groups. 
 One dose group Two doses group 
Productivity   
Pigs placed (pigs/group) 10,000 10,000 
Average days on feed (days/pigs) 160 160 
Average start weight (kg/pig) 5.44 5.44 
Wean to finish mortality (% of pigs placed) 10.54% 8.68% 
Wean to finish ADG (kg/day) 0.7805 0.7805 
Wean to finish FC (kg of feed/kg of gain) 2.2938 2.2749 
Revenue and production costs   
Market pig price ($/kg) $1.14 $1.14 
Fixed costs ($/pig) $11.79 $11.79 
Weaned pig costs ($/pig) $42.86 $42.86 
Feed costs ($/kg of feed) $0.24 $0.24 
Other variable costs ($/pig) $19.75 $19.75 
Vaccination costs   
Vaccine cost ($/pig) $1.00 2.00 





A sensitivity analysis was conducted using the Data Table function on Microsoft Excel 
(version 16.16.26, Microsoft Corporation, Redmond, WA) to describe how the differences in the 
vaccination costs and in the market pig prices would change the benefit-cost ratio of the second 
MLV vaccination dose. The changes in prices that were applied in sensitivity analysis were 
based on changes of $20 on the market price of a 122 kg pig and on changes of $0.20 on the cost 
of the second vaccination dose.  
 
Results 
The study included 42 batches of growing pigs that were vaccinated with two doses and 
39 batches of growing pigs that were vaccinated with only one dose of Ingelvac PRRS® MLV 
vaccine (table 5-2). There were 136,482 pigs, 634 sample collection events, and 3,646 oral fluid 
samples. 
Additionally, eight batches of growing pigs that were vaccinated with two doses and 
eight batches of growing pigs that were vaccinated with one dose, from one of the PRRSV 
positive-stable farms, were excluded from the study and not included in the statistical analysis 
due to severe weather-related events that affected the closeout performance indicators of the 
batches. Also, two batches of growing pigs that were vaccinated with two doses and two batches 
of growing pigs that were vaccinated with one dose, from another PRRSV positive-stable sow 
farm, were excluded from the study and not included in the statistical analysis due to the mixing 
of growing pigs from different MLV vaccination groups, during the transfer from nursery to 





Table 5-2. Baseline demographic characteristics of one dose and two doses groups. 
Characteristics One dose group Two doses group 
Weight started, kg (mean ± 
standard deviation) * 
6.79 ± 0.87 6.84 ± 0.86 
Average days on feed (mean ± 
standard deviation) * 
160 ± 7.42 159 ± 7.03 
Pigs started (mean ± standard 
deviation) 
68,511 ± 1,214 67,971 ± 1,023 
Number of eligible batches 
started 
39 42 
Number of PRRSV positive-
stable batches 
33 33 
Number of PRRSV positive-
unstable batches 
6 9 
* There was no statistical difference of any characteristic between groups at P <0.05. 
 
 Virus detection comparison 
For batches originated from PRRSV positive-stable sow farms, the proportion of wild-
type PRRSV detection on oral fluids samples from the one dose group (21.23%) was 
significantly higher than the proportion from the two doses group (17.06%) (p=0.0082) with a 
risk ratio of 1.24 (95% CI: 1.07 – 1.43). However, when batches were originated from PRRSV 
positive-unstable sow farms, the proportion of wild-type PRRSV detection on oral fluids samples 




(p=0.3707). The comparisons of the proportion of wild-type PRRSV detection in oral fluids 
between one dose and two doses groups at each of the sampling events are shown in Figure 5-2. 
 
 
Figure 5-2. Proportion of wild-type PRRSV detection in oral fluids samples over time for one 
dose and two doses groups. 
 
For batches originated from PRRSV positive-stable sow farms, the log counts of viral 
RNA per ml of oral fluids from the one dose group (1.29 copies/ml) were not significantly higher 
than that of the two doses group (1.10 copies/ml) (p=0.0532), with a rate ratio of 1.17 (95% CI: 
0.99 – 1.37). For batches originated from PRRSV positive-unstable sow farms, the log counts of 
viral RNA per ml of oral fluids between one dose group (2.74 copies/ml) and two doses group 
(2.53 copies/ml) were not significantly different (p=0.4848). The comparisons of the log counts 
of viral RNA per ml of oral fluids between one dose and two doses groups at each of the 






Figure 5-3. Log counts of wild-type PRRSV RNA per ml of oral fluids over time for one dose 
and two doses groups. 
 
 Productivity performance comparison 
Overall, the one dose group had 10.54% of wean-to-finish mortality, and the two doses 
group had 8.68%. The p-value was <0.0001 and the rate ratio was 1.21 (95% CI: 1.16 – 1.27). 
Considering only batches originated from PRRSV positive-unstable herds, the one dose group 
had 17.99% of wean-to-finish mortality, and the two doses group had 13.52%. This represents a 
reduction of 4.47 percentage points on the wean-to-finish mortality of the two doses group 
compared to the one dose group, with a p-value <0.0001 and rate ratio of 1.30 (95% CI: 1.22 – 
1.44). Considering only batches originated from PRRSV positive-stable herds, the one dose 
group had 6.18% of wean-to-finish mortality, and the two doses group had 5.57%. This 




group compared to the one dose group, with a p-value <0.0001 and rate ratio of 1.11 (95% CI: 
1.05 – 1.16) (Figure 4). 
 
 
Figure 5-4. Comparison of wean-to-finish mortality rate between one dose and two doses groups, 
by source sow farm PRRSV status (means and standard errors). 
 
The effect of the second MLV vaccination dose to reduce wean-to-finish mortality 
increased when there was higher frequency of wild-type PRRSV detection and higher diversity 
of wild-type detection during the growth phase. The mortality rate of one dose group was lower 
than that of two doses group when there was no wild-type PRRSV detection during the growth 
phase (Figure 5). No significant differences in average daily gain (Table 3) and feed conversion 






Figure 5-5. Comparison of wean-to-finish mortality rate between one dose and two doses groups, 
by the frequency and the diversity of wild-type PRRSV detection. 
 







































































 Economic performance comparison 
Based on the changes in productivity reported by the regression models, the net profit of 
the two doses group was $2,242 higher than the net profit of the one dose group. The vaccination 
costs with two doses was $11,000 higher than the costs of vaccinating pigs with only one dose. 
As the difference in net profit was higher than the difference in vaccination costs, the second 
MLV vaccination dose was considered economically beneficial, with a benefit-cost ratio of 1.83 
(Table 5). When including only batches from PRRSV positive-unstable sow farms, the benefit 
cost-ratio of the second MLV vaccination was 4.45, while for batches originated from PRRSV 












Productivity    
Average final weight (kg/pig) 130.3 130.3 0 
Total weight produced (kg/group) 1,165,843 1,190,082 24,240 
Feed fed per group (kg of feed/group) 2,562,579 2,594,305 31,726 
Revenue and production costs    
Revenue ($/group) $1,332,719 $1,360,428 $27,709 
Fixed costs ($/group) $117,900 $117,900 $0 
Weaned pig costs ($/group) $428,600 $428,600 $0 
Feed costs ($/group) $603,139 $610,606 $7,467 
Other variable costs ($/group) $197,500 $197,500 $0 
Net profit ($/group)  -$14,421 $5,821 $20,242 
Vaccination costs    
Vaccine and labor costs ($/group) $11,000 $22,000 $11,000 
Benefit-cost ratio   1.83 
 
The second MLV vaccination dose was economically beneficial when vaccination costs 
were lower than $2.17 per dose or when the market pig prices were higher than $0.74/kg. 
Differences in the benefit-cost ratio of the second MLV vaccination with varying market pig 










This multi-source randomized field study sought to characterize wild-type PRRSV 
detection on oral fluids, as well as productivity and economic performance of batches of growing 
pigs immunized with two doses of Ingelvac PRRS® MLV vaccine, compared to batches 
vaccinated with a single dose of the same vaccine. A randomized blocking design was used to 
allocate the two vaccination protocols into the pig batches. The growing pig populations of this 
study were selected to reflect those originated from PRRSV-positive breeding herds, and placed 
in high-pig dense areas (i.e., high risk of exposure to wild-type PRRSV). These criteria were 
implemented to assure natural wild-type PRRSV exposure to the growing pig batches since this 
was a field trial, and no experimental PRRSV challenge model was implemented.  
Overall, the wild-type PRRSV detection in oral fluids samples from two doses group was 
lower than that of one dose group. A reduction in the extent of wild-type PRRSV detection on 
oral fluids samples from two doses group, compared to the one dose group, was more evident on 
batches from PRRSV positive-stable sow farms than in batches originated from PRRSV positive-




PRRSV positive-stable sow farms, compared to one dose group, was higher on the sampling 
events collected at weeks seven, 10, and 19 of age. These results suggest a potential benefit for 
vaccinating pigs from PRRSV positive-stable sow farms with the two doses of PRRS MLV 
vaccine to reduce wild-type PRRSV detection during the wean-to-finish phase. Low wild-type 
PRRSV circulation at growing pig sites may help to reduce the risk of PRRSV outbreaks in 
neighbor sow farms [38]. No major differences were detected between one dose and two doses 
groups originated from PRRSV positive-unstable sow farms, perhaps due to the high prevalence 
of wild-type PRRSV at the time of placement of pigs into the growing pig sites.  
Differences in the RFLP cut patterns detected at each sampling event were used as a 
measure for the diversity of virus detection within each batch of growing pigs. In the absence of 
other practical methods, the RFLP was selected in order to facilitate communication across field 
veterinarians, since it is reported in diagnostic report from most swine-centric veterinary 
diagnostic laboratories in the USA. Results describing the diversity of virus detection over time 
using the RFLP cut patterns were similar to those obtained when using a cut off of 1% of genetic 
differences in the ORF-5 sequencing (data not presented).   
Significant differences (at alpha level of 0.05) in productivity parameters between two 
doses and one dose groups were detected only for mortality. The effect size was higher on 
batches originated from PRRSV positive-unstable sow farms than in batches from PRRSV 
positive-stable sow farms. The effect size also increased in batches with a higher frequency of 
wild-type PRRSV detection and with higher diversity of wild-type PRRSV detection during the 
growing phase. The Poisson regression model was very sensitive for detecting differences in 
mortality between vaccination groups, however significant differences in growth performance 




study only had 5% of power to detect significant difference in the observed average daily gain 
and 16% of power to detect significant difference in the observed feed conversion between one 
dose and two doses groups. In order to detect significant differences with 80% of power, the 
differences in average daily gain and in the feed conversion between one dose and two doses 
groups would have to be at least 0.047 and 0.055, respectively. Moreover, it is important to note 
that although no significant differences were detected on growth parameters, all measures of 
effects detected were reporting improvements on the two doses group. 
While results from this study showed a reduction in mortality of batches of pigs 
vaccinated with two PRRSV MLV doses, recent studies proposing a DNA-MLV prime-boost 
strategy regimen (vaccinating pigs with a DNA vaccine and applying a PRRS MLV vaccine a 
few weeks afterwards) improved the immune response, but not the clinical response against 
heterologous PRRSV infection. The DNA-MLV prime-boost strategy improved PRRSV-specific 
cellular response and increased the neutralizing antibody titers on one study [29] and slightly 
improved the T cell response, with a substantial increase in the PRRSV specific antibody 
response on a different study [26]. In fact, the strategy of using two doses of PRRSV MLV 
vaccination on growing pigs from a unidirectional flow was effective to control PRRSV from 
finishing populations. The vaccination protocol was carried out with all pigs within the facility 
receiving an intramuscular vaccination with 2.0 mL of PRRS MLV vaccine, which was repeated 
thirty days later. Authors hypothesized that multiple doses of vaccine would help to reduce the 
spread of virus, and to reduce the risk of improperly vaccinating or nonvaccinating pigs existing 
in the population [35]. Differences in productivity and in wild-type PRRSV detection between 




response [39], humoral immune response [25, 26], or both [25, 28]. However, further studies are 
necessary to clarify this research question.  
The economic analysis presented in this study demonstrated that it was economically 
beneficial to use the second MLV vaccination dose to immunize batches of growing pigs. Based 
on the changes in productivity reported by the regression models, the improvement in the net 
profit of the two doses group represented 183% of the increase in the cost of vaccination. The 
second MLV vaccination was even more economically beneficial for batches originated from 
PRRSV positive-unstable sow farms, due to the higher differences in productivity reported. 
However, for batches originated from PRRSV positive-stable sow farms, the second MLV dose 
was only economically beneficial when market pig prices were higher than $1.47/kg and when 
vaccination costs were lower than $0.75. The prices applied to this study were calculated based 
on the monthly average sales value in dollars from December of 2018 to November of 2019 
(http://www2.econ.iastate.edu/estimated-returns).  
The vaccine applications were made by farm staff, and no adverse effects were reported 
for neither one dose nor the two doses groups. A limitation of this study was that it did not 
include diagnostic information of other pathogens of interest in swine production. The study also 
did not measure the changes in cell-mediated immune response nor on humoral immune 
response between one dose and two doses groups.  
 
Conclusions 
The proportion of wild-type PRRSV detection on oral fluids samples and the log counts 
of viral RNA per ml of oral fluids from the two doses group was lower than the one dose group 
when batches originated from PRRSV positive-stable sow farms, with a risk ratio of 1.24 and a 




the one dose group, with a rate ratio of 1.21. The effect size was higher on batches from PRRSV 
positive-unstable sow farms, and on batches with higher frequency and diversity of wild-type 
PRRSV detection during the growing pig phase. No differences in growth performance (average 
daily gain or feed efficiency) were detected between two doses and one dose groups. The second 
MLV vaccination dose was economically beneficial, with benefit-cost ratio of 1.83. For batches 
originated from PRRSV positive-unstable farms, the benefit-cost ratio was 4.45 and for batches 
originated from PRRSV positive-stable farms, the benefit-cost ratio was 0.45. 
Under the conditions of this study, vaccinating growing pig batches with two doses of 
PRRS MLV vaccine was a useful strategy to immunize growing pigs against PRRSV, lowering 
the wild-type PRRSV detection, lowering growing pig mortality rate, and increasing growing pig 
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CHAPTER 6.    GENERAL CONCLUSIONS 
Porcine reproductive and respiratory syndrome (PRRS) virus has been present in the 
global swine industry for over 30 years and it still causes significant economic impact to the 
production due to reproductive disorders and respiratory disease. In response, the swine industry 
has been developing strategies to minimize losses associated with the disease, which include 
improving diagnostics, control and elimination programs, and immunization practices. PRRS 
modified-live virus (MLV) vaccines are widely used around the world to expose swine 
populations to PRRSV and mitigate the consequences of wild-type (aka field) virus infections. 
However, only partial protection is expected when animals are subsequently challenged with 
heterologous strains. Due to the high genetic diversity of circulating virus in the field, and the 
varying factors affecting vaccine efficacy under field conditions, there is the need to further 
understand the dynamics and spread of viral infections in growing pigs, as well as the effect of 
different strategies to immunize pig populations to PRRSV. 
In this dissertation, Chapter two described the impact that the practice of mass 
vaccinating sows from PRRSV positive-stable farms, using PRRS MLV vaccine, has on 
subsequent nursery pig productivity performance. Batches of nursery pigs started up to 12 weeks 
after the PRRS MLV mass sow vaccinations were classified into four post-mass sow vaccination 
groups. Batches started up to six weeks before the mass interventions were classified into the 
baseline production group. Results described that the post-mass sow vaccination groups had 
significantly higher mortality rate than the baseline group. Based on the differences in 
productivity (with significance level lower than 0.25) the post-mass sow vaccination groups 
produced less pigs, but had a higher average weight gain than the baseline group. Overall, the 




produced by four baseline production groups of the same size was 1.02.  Only batches started 
four to six weeks after the PRRS MLV sow mass vaccinations had a total weight produced lower 
than baseline group, which may be due to the fact that at the moment of the PRRS MLV mass 
sow vaccinations most of the pigs were at the latest stages of gestation. The lack of diagnostic 
information about wild-type PRRSV circulation on the batches of nursery pigs was an important 
limitation of this study. To the best of our knowledge this was the first study describing this 
safety measure of the PRRS MLV vaccine under field conditions. According to the results of this 
study, mass vaccination of sows with PRRS MLV vaccine with the intent to immunize swine 
breeding herds to PRRSV was not associated with a negative impact on the productivity of the 
batches of nursery pigs flowing downstream. 
Chapter three introduced different patterns of wild-type PRRSV detection over time in 
PRRS MLV-vaccinated growing pig batches. Additionally, it assessed how each pattern of 
detection was associated with growing pig mortality. All batches of growing pigs were originated 
from PRRSV positive-stable and unstable sow farms and vaccinated with two different doses of 
PRRS MLV vaccine. Six oral fluids samples were collected from all pig batches with intervals of 
three weeks and tested for detection of wild-type PRRSV. It was demonstrated that more than 
90% of the batches of growing pigs were detected with wild-type PRRSV-2 (aka North-
American), while 38% of the batches were detected with wild-type PRRSV-1 (aka ‘European’). 
Four distinct patterns of wild-type PRRSV-1 were identified. However, detection of wild-type 
PRRSV-1 was not associated with significantly increase of growing pig mortality. For wt-
PRRSV-2, five patterns of detection were identified. Growing pig mortality was higher in 
batches with wild-type PRRSV-2 detection in earlier stages of life. However, mortality rate of 




vaccinated with two doses of PRRS MLV vaccine, compared to batches that received only one 
dose. Limitations of this study includes results being based on ORF-5 nucleotide sequencing (not 
whole genome sequencing) of only one RT-qPCR positive sample (not all the six samples) at 
each sampling event. Results described on this chapter highlights that batches of growing pigs, 
originated from PRRSV positive farms and raised in areas of high pig density, are very likely to 
be exposed to the wild-type PRRSV-2 during the growth phase, despite being previously 
vaccinated with PRRSV MLV vaccine. It was also demonstrated the potential benefit of focusing 
on biosecurity practices, especially in the early phases of production, to avoid wild-type PRRSV-
2 introductions on batches of pigs and to reduce mortality associated with the disease. 
Additionally, results suggested that vaccination with two PRRS MLV doses was associated with 
lower mortality rate, when growing pig populations had early wild-type PRRSV-2 exposure.  
Chapter four sought to compare productivity and economic performance between batches 
of nursery pigs vaccinated with a full dose of PRRS MLV vaccine and batches vaccinated with 
only half of the dose of the same vaccine. The study included retrospective data from nursery pig 
batches originated from PRRSV positive-stable sow farms and raised in areas of high pig 
density. The full MLV dose group had significantly higher average daily gain than the half MLV 
dose group. However, no significant differences were detected on the mortality rate and on the 
feed conversion between groups. Based on changes in productivity detected, the full MLV dose 
vaccination was economically beneficial, with a benefit-cost ratio of 2.16, compared to the 
vaccination with only half MLV dose. Limitations of this study included the fact that the 
vaccination protocols were not allocated to groups following a randomized process and also that 
there was no diagnostic monitoring to confirm challenge with wild-type PRRSV during the 




dose of PRRS MLV vaccine was associated with improved nursery pig productivity and nursery 
pig profitability, compared to the vaccination with only half dose of the same vaccine. 
Chapter five sought to characterize wild-type PRRSV detection on oral fluids, as well as 
productivity and economic performance of batches of growing pigs vaccinated with two doses of 
Ingelvac PRRS® MLV vaccine, compared to batches vaccinated with a single dose of the same 
vaccine. All batches of growing pigs included in the study originated from PRRSV positive-
stable or PRRSV positive-unstable sow farms and were placed in areas of high pig density. 
Results demonstrated that the proportion of wild-type PRRSV detection on oral fluids samples 
and the log counts of viral RNA per ml of oral fluids from the two doses group was lower than 
the one dose group, when batches originated from PRRSV positive-stable farms. The mortality 
rate of the two doses group was significantly lower than that of the one dose group, with a higher 
effect size when batches originated from PRRSV positive-unstable sow farms and on batches 
with higher frequency and with higher diversity of wild-type PRRSV detection. Overall, it was 
economically beneficial to use the second dose of MLV vaccination to immunize batches of 
growing pigs compared to using only one MLV vaccination dose, especially when batches were 
originated from PRRSV positive-unstable sow farms. The absence of measures of cell-mediated 
immune response and humoral immune response between the two doses and the one dose groups 
was a limitation of this study. Under the conditions of this study, vaccinating growing pig 
batches with two doses of PRRS MLV vaccine with the intent to immunize growing pigs against 
PRRSV lowered the wild-type PRRSV detection, reduced growing pig mortality rate, and 





Additional research designed to compare the cell-mediated and humoral immune 
response after immunizing groups of growing pigs with different PRRS MLV vaccination 
protocols is needed. There is also the need to conduct randomized field trials seeking to compare 
wild-type PRRSV detection, antibody responses, key productivity parameters and economic 
performance between populations of growing pigs vaccinated with a half MVL dose and with 
two half MLV doses (split dose).  
Results presented in this dissertation provide field-relevant information on the effect of 
different PRRS vaccination strategies on growing pig performance, as well as data on dynamics 
of wild-type PRRSV detection in oral fluids at population level during the growing phase of 
production. The results will allow veterinarians and producers to make evidence-based decisions 
to proactively influence herd immunity of growing pig batches at risk of wild-type PRRSV 
infection, and consequently maximize pig performance and increase the success of projects to 
control and eliminate PRRSV at a regional level. 
